

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol for the cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041677
Article Type:	Protocol
Date Submitted by the Author:	14-Jun-2020
Complete List of Authors:	<p>Jayamaha, Akila; KIU, Health Sciences Perera, Chamilya; KIU, Health Sciences Orme, Mark; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Jones , Amy; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Wijayasiri, Upendra; Colombo South Teaching Hospital, Sports Medicine Unit Amarasekara, Thamara; University of Sri Jayewardenepura, Faculty of Allied Health Sciences Karunatilake, Ravini ; National Hospital of Sri Lanka, Central Chest Clinic Fernando, Amitha; National Hospital of Sri Lanka, Central Chest Clinic Seneviratne, Anthony ; Primary Care Respiratory Group Barton, Andy; University of Plymouth, Faculty of Health Jones, Rupert; University of Plymouth, Faculty of Health Miah, Ruhme ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory Malcolm, Dominic; Loughborough University, School of Sport, Exercise and Health Sciences Matheson, Jesse; University of Sheffield, Department of Economics Free, Robert; University of Leicester, Department of Respiratory Sciences, Manise, Adrian ; University of Leicester, Department of Respiratory Sciences Steiner, michael ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory Wimalasekera, Savithri; University of Sri Jayewardenepura, Faculty of Medical Sciences Singh, Sally; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory
Keywords:	REHABILITATION MEDICINE, Chronic airways disease < THORACIC MEDICINE, Emphysema < THORACIC MEDICINE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Protocol for the cultural adaptation of Pulmonary Rehabilitation and subsequent testing in**
5 **a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary**
6 **Disease in Sri Lanka**
7
8
9

10 Akila R Jayamaha ¹, Chamilya H Perera ¹, Mark W Orme ^{2,3}, Amy V Jones ^{2,3}, Upendra K D C
11 Wijayasiri⁴, Thamara D Amarasekara⁵, Ravini de S Karunatillake ⁶, Amitha C Fernando ⁶, Seneviratne A
12 L P De S.⁷, Andy Barton ⁸, Rupert Jones ⁸, Ruhme B Miah^{2,3}, Dominic Malcolm⁹, Jesse A Matheson ¹⁰,
13 Robert C Free³, Adrian Manise³, Michael C Steiner^{2,3} Savithri W Wimalasekera ¹¹, Sally J Singh ^{2,3}
14

15 Correspondence to Akila Randika Jayamaha/1226arj@gmail.com/akila@kiu.ac.lk
16

17 **Abstract**
18

19
20 **Introduction** International guidelines recommend pulmonary rehabilitation (PR) should be
21 offered to adults living with COPD, but there is limited PR available in Sri Lanka. Culturally
22 appropriate PR needs to be designed and implemented in Sri Lanka. The study aims to adapt PR
23 to the Sri Lankan context and determine the feasibility of conducting a future trial of the adapted
24 PR in Sri Lanka.
25
26
27

28
29 **Methods and analysis** Phase-1: Develop the intervention: Focus groups with adults living with
30 COPD and caregivers and in-depth interviews with healthcare professionals will be conducted to
31 inform PR adaptations. Phase-2: Randomised controlled feasibility trial conducted in Central
32 Chest Clinic, Colombo, Sri Lanka. Eligible participants will be identified and will be invited to
33 take part. A total of 60 participants will be recruited to the trial and randomised (1:1) into one of
34 two groups; control group receiving usual care or the intervention group also receiving PR. The
35 PR programme is likely to consist of 12 sessions of exercises and health education, delivered
36 twice weekly. After completion of PR, routine measures in both groups will be assessed by a
37 blinded assessor. The primary outcome measure is feasibility, including assessing eligibility,
38 uptake and completion. Phase-3: Qualitative evaluation of the trial: Focus groups with
39 participants and in-depth interviews with PR deliverers will be conducted to further determine
40 feasibility and acceptability of PR, as well as ability to run a larger trial.
41
42
43
44
45
46
47
48
49
50

51 **Ethics and dissemination** Ethical approval will be obtained from the ethics review committee of
52 the Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and the
53 University of Leicester, UK. The results of the trial will be disseminated through patient and
54
55
56
57
58
59
60

1
2
3 public involvement events, local and international conference proceedings, and peer-reviewed
4 journals.
5

6
7
8 Trial registration: Phase-1) ISRCTN58273367, Phases-2 &3) ISRCTN13367735
9

10 **Keywords:** COPD, Pulmonary Rehabilitation, Exercise, Education, Sri Lanka
11

12 **Strengths and limitations**

- 14 • This study is the first examining the feasibility and acceptability of a culturally
15 appropriate pulmonary rehabilitation programme for adults with COPD in Sri Lanka.
16
- 17 • Taking a mixed-method approach, this study will provide a rich insight into delivering a
18 trial of pulmonary rehabilitation in the Sri Lankan context.
19
- 20 • This study is a single center feasibility trial. As such, whilst findings will be an important
21 first step in understanding the potential role of pulmonary rehabilitation in Sri Lanka and
22 low- and middle-income countries more broadly, findings may not be generalizable to
23 other regions of the world.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a progressive disease characterised by airflow obstruction and breathlessness. COPD is a major cause of morbidity and mortality throughout the world, corresponding to 6% of all deaths worldwide.¹ Further, more than 90% of COPD deaths occur in low and middle-income countries.² The most recent estimate of COPD prevalence in South Asia was 6.3%³ with a prevalence in Sri Lanka of 10.5%,⁴ similar to the estimated global COPD prevalence of 11.7%.⁵ COPD is a significant burden to both patients and healthcare services.⁶

Chronic cough with sputum, breathlessness, physical inactivity and exercise intolerance resulting from dyspnoea or fatigue are common consequences of COPD.¹ Symptoms of COPD progressively worsen and people can become breathless, even at rest. Daily activities often become difficult as the condition worsens, impacting their quality of life.⁷ The impact of COPD to the individual and to society makes the need for interventions to reverse the associated disability of paramount importance.

The development of rehabilitation in low-income and middle-income countries will ensure the Universal Health Coverage.⁸ International guidelines recommend that pulmonary rehabilitation (PR) should be routinely offered to patients with chronic respiratory disease who have persistent symptoms, limited activity, and/or are unable to adjust to illness.⁹ It is a low cost, high impact intervention that improves the quality of life, reduces suffering, reduces mortality and reduces economic loss, relieves dyspnoea and fatigue, improves exercise capacity, improves psychological and emotional function, and enhances an individual's self-management of their condition.¹ Having realised the benefits of PR in COPD, Western countries have incorporated this as an important structural component of healthcare delivery services.¹⁰ Implementation of PR based as practiced in Western countries in Sri Lanka requires adaptation to the local health service, population and culture. Despite its effectiveness, there is a significant need to understand the feasibility of conducting PR in low resource Sri Lankan health care setting and the acceptability of PR among Sri Lankan adults living with COPD and healthcare staff involved in its delivery. Uptake and completion of PR even in Western countries is an on-going challenge.¹¹ The need to maximize appeal of PR to patients and referrers is a global issue and one that is

likely to be specific to a given location and population. There remains an unmet need for PR in Sri Lanka. To be successful, PR must be not only evidence-based, but also designed and implemented in a manner sensitive to the context in which it is being delivered, such as culture and geography. Therefore, the aim of this study is to devise an appropriate PR programme and then determine the feasibility and acceptability of this programme for adults living with COPD in Sri Lanka and assess the potential for a future trial of its effectiveness.

The objectives of the study are to:

1. Explore the needs and perceptions of adults living with COPD, their care-givers /family members and health care professionals to inform the adaptations required for a PR programme suitable for the Sri Lankan context.
2. Determine the feasibility of conducting adapted hospital-based PR for people living with COPD.
3. Assess the acceptability of the PR among Sri Lankan adults living with COPD and healthcare staff involved in its delivery.
4. Describe any changes in health of the adults living with COPD following completion of PR.
5. Assess the feasibility of a future trial and estimate the required sample size.

METHODS AND ANALYSIS

Study design and registration

The proposed study will be conducted in three phases. Phase 1: A qualitative study will be conducted to inform the adaptations required to make PR specific to the Sri Lankan context. Phase 2 is a single blind randomised control feasibility trial. Adults living with COPD will be randomised (1:1) into adapted PR or usual care. Phase 3: Qualitative evaluation of the trial to determine the feasibility and acceptability of PR deliverers and participants. The trial will be conducted, analysed and reported according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement¹² and trial has been registered on the ISRCTN website. The design of the study and flow of participant enrolment is presented in figure 1.

Study setting

The study will be carried out at the Central Chest Clinic, Colombo, Sri Lanka which is a leading health care facility that provides treatment for adults with respiratory disease. A room allowing confidential discussions will be used for conducting focus group discussions among adults living with COPD, their caregivers /family members, and nurses. Semi structured interviews will be conducted among doctors and physiotherapists in the conference hall (which is quiet and not used routinely for work) or consultation rooms as convenient to them and without interfering with their routine work. The venue for PR will be a large room at the Central Chest Clinic.

Participants

Key informants and suitable participants for phase 1 of the study will be identified by the researchers with the help of health care professionals involved in the treatment of COPD at Central Chest Clinic. Suitable participants (adults living with COPD, their caregivers /family members, nurses, doctors, physiotherapists) will be selected using purposive sampling method. Multi-religious and multi-ethnic Sri Lankan cultural diversity and gender will be considered when recruiting to the study. Participants who provide written informed consent will be enrolled in the study.

After the adaptation of PR in phase 1, suitable participants for the Phase 2 randomised controlled feasibility trial will be identified by the Medical Officers in the Chest Clinic and will be invited to take part in an eligibility assessment. This assessment will determine eligibility for entry into the study. People eligible for inclusion in the trial will be: aged ≥ 18 years, will have a clinically confirmed diagnosis of COPD by a physician, confirmed COPD with spirometry based on GOLD criteria with $FEV_1/FVC < 0.7$, and $FEV_1 < 80\%$ predicted, ≥ 1 exacerbation per year, mMRC grade ≥ 2 and willing to provide informed consent. Adults with comorbidities such as severe or unstable cardiovascular, other internal diseases and locomotor difficulties that preclude the exercise or malignant disease or other serious illness which will interfere with participation in the PR, will be excluded from the study. Individuals not eligible for the study will be recorded on a study screening log.




Figure 1: Flow of participant of the three phases of the study

Procedure

Eligible participants will be informed verbally about the study by the Medical Officers of the Central Chest Clinic. After receiving a study information sheet, potential participants will be contacted to arrange an appointment, if they wish to take part. An opportunity to ask questions will be provided. If willing to take part in the study, they will be asked to provide written informed consent. Information regarding the interest of participation in the study will be taken as field notes. Baseline outcome measures will be assessed. After baseline data collection, participants will be randomised (1:1) into two groups. One group will receive usual care and PR and the other group will receive only usual care which consists of pharmacological treatment and brief information about disease condition, medication and inhaler techniques. Experiences of the participants and PR deliverers regarding the acceptability and feasibility of PR will be explored in interviews and focus groups during Phase 3 of the study. Participants who did not complete the PR will be asked to take part in a drop-out interview and information provided freely by the participants will be collected as field notes.

Trial interventions

Intervention: Adapted pulmonary rehabilitation

Sri-Lankan specific PR will comprise the core elements of an evidence based rehabilitation, a programme of exercises^{13, 14} and health education.^{13, 14, 15} The detail of delivery and adaptations of PR will be informed by collecting the views and opinions from adults living with COPD, their family caregivers, and healthcare professionals. PR is typically a 6-week rolling programme and consisting of 12 sessions in total, delivered twice a week.^{13, 14} Sessions usually last approximately two hours, with one hour for exercise training and one hour for education. The duration of the PR trial and frequency and duration of sessions will be discussed during Phase 1. All staff delivering PR will be trained and assisted by a nursing officer, a clinical nutritionist, an exercise physician and a physiotherapist. The venue for PR will be at the Central Chest Clinic, Colombo, Sri Lanka. The Central Chest Clinic will have a maximum capacity of 10 patients per PR class. The equipment required will be simple and include chairs, weights, and simple exercise equipment based on local availability, suitability and informed by qualitative work.¹⁶

In keeping with evidence-based guidelines^{13, 14}, discussions in Phase 1 will include the core exercise component of PR, notably resistance training (e.g. upper and lower limbs) and aerobic training (walking, sit-to-stand, step-ups) using minimal equipment and education. Each participant's exercise regimen will be individually prescribed and progressed¹⁷ with walking speed will be prescribed using the ISWT.¹⁸ The process in which this is achieved by patients will be informed by Phase 1. The education component will be delivered by an interdisciplinary team and will be informed by qualitative findings from Phase 1 with discussions facilitated by usual education topics as described in guidelines.^{13, 14}

Usual care

Usual care will consist of pharmacological treatment and optimization, prescribed to patients after consultation with Medical Officers at the Central Chest Clinic. Brief information about disease condition, medication and inhaler techniques will be provided by Medical Officers and Nurses. Pulmonary rehabilitation or any form of exercise recommendation is not part of usual care.

Outcomes

Primary outcome

The primary outcome of the trial will be the feasibility and the acceptability of the PR intervention.

Feasibility

Measures to assess feasibility are provided in table 1 and include the comprehensive assessment of the feasibility of patient recruitment and the intervention delivery.

Table 1: Primary outcome measures- Feasibility and operational experience assessment

Feasibility of patient recruitment	Data sources
Feasibility of screening and recruiting participants	Interviews with the healthcare professionals, screening log
Suitability of the inclusion criteria	Interviews with the healthcare professionals, screening log

Number of eligible patients, number of patients screened, number of patients invited to take part, actual number of participants who consent to take part	Screening log
Number of patients who refuse, drop out and the reasons for refuse and drop out	Interviews with the patients, screening log
Operational experience of intervention delivery	
Service provider and multi-disciplinary teams' willingness and ability to deliver the PR	Interviews with healthcare professionals
The practicality of delivering the intervention in the proposed setting	Interviews with healthcare professionals and focus groups with participants
The time needed to collect the data Baseline visit- Time taken for each measure (each individual questionnaire and physical measure) Follow-up visit- Time taken for each measure (each individual questionnaire and physical measure)	Interviews with the healthcare professionals, Rehabilitation records
Data completeness and accuracy	Interviews with the healthcare professionals, Rehabilitation records, RedCap
Adherence to home exercise	Interviews with the patients and self-report exercise diary
The training and resources needed to deliver the intervention (ensuring readiness for a future much larger multi-center trial)	Interviews with the healthcare professionals and focus groups with participants, Rehabilitation records
Description of unintended events	Adverse events log, REDCap

Acceptability

The acceptability of the PR intervention among adults living with COPD and healthcare staff involved in its delivery will be assessed. Participants' experience of the PR, including any perceived benefits, challenges and changes they would make to the programme, will be explored in qualitative interviews and focus groups after their discharge assessment or withdrawal. The experience of healthcare professionals regarding the PR intervention, such as their confidence in delivering the programme, the components of PR, structure of PR, the patient adherence to the PR exercises and how their perceptions changed over the course of the trial, will be explored in qualitative interviews at the end of the trial.

Secondary outcomes

The secondary outcomes of this study are provided in table 2. Comparison of secondary outcome measures of baseline and post intervention, will describe any changes in the health of the adults living with COPD following completion of PR

Table 2: Secondary outcome measures

Outcome measures	Baseline	Post-intervention
Socio-demographics	x	
Lung health (spirometry data, smoking status, number of COPD exacerbations in the last year)	x	
Comorbidities	x	
Treatments	x	
Nutritional status (Body Mass Index, mid upper arm circumference, skinfold thickness, self-report seven-day diet diary)	x	x
Disease burden (MRC dyspnea grade, CAT, CCQ)	x	x
Economic impact of disease (WPAI)	x	x
Quality of life (EQ-5D-5L)	x	x
Psychological wellbeing (Hospital Anxiety and Depression scale)	x	x
Physical function (5x sit-to-stand test)	x	x
Exercise capacity (ISWT, ESWT)	x	x
Accelerometer assessed physical activity (ActiGraph wGT3x-BT)	x	x

MRC - Medical Research Council, CAT- COPD Assessment Test, CCQ - Clinical COPD Questionnaire, EQ-5D-5L - EuroQol Five Dimensions Five Levels, ISWT - Incremental Shuttle Walk Test, ESWT - Endurance Shuttle Walk Tests, WPAI – Work Productivity and Activity Impairment questionnaire

Sample size and recruitment target

This study is a feasibility trial that aims to provide data for an accurate estimation of the required sample size for future trials. Therefore, a formal sample size calculation is not required. We aim to recruit and randomise 60 participants to the study (30 in each group).

Patient allocation, concealment, and blinding

Randomisation will occur through random permuted blocks to either the intervention group (PR+ usual care) or control group (usual care) in ratio 1:1 using Sealed envelope™.

The computer-generated patient allocation sequence will be monitored by an individual who is independent of the research team and will inform the research team of group allocations via telephone. Participants will be informed about their group allocation after providing informed consent and completing baseline assessments.

1
2
3 It will not be possible to blind patients to their group allocation due to the nature of PR. Research
4 staff will be blinded to outcome measures. Participants will be advised not to reveal their group
5 during the follow-up assessment. Any episodes of un-blinding will be documented and reported.
6
7

8 9 **Data collection**

10 11 *Phase 1: Qualitative assessment for adaptation of PR*

12 13 **Focus groups with patient and family caregivers**

14
15 Focus groups with adults living with COPD and separate focus groups with their family
16 members/ caregivers will be conducted until data saturation. We anticipate conducting up to 5
17 focus groups with 6-8 participants in each. Data will be collected during patients' clinic visits.
18 Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes,
19 and will be conducted face-to-face by an interviewer and note-taker (observer). Focus groups
20 will be transcribed verbatim, with identifiable information removed. Envisaged outcomes of the
21 focus groups will include Sri Lankan specific adaptation of PR.
22
23
24
25
26
27
28
29

30 31 **Interviews with healthcare professionals involving the treatment of COPD**

32
33 Up to 15 in-depth interviews with healthcare professionals will be conducted until data
34 saturation. Structured interviews will be conducted with healthcare professionals as convenient
35 to them without interfering with their routine work. Interviews will be audio-recorded and will
36 be conducted face-to-face by an interviewer. Interviews will be transcribed verbatim, with
37 identifiable information removed. Envisaged outcomes of the in-depth interviews will be a
38 suitable design and content of PR acceptable respiratory health care deliverers in Sri Lanka.
39
40
41
42
43

44 45 *Phase 2: Single blind randomised control feasibility trial*

46 Data will be collected by trained researchers, following standard operating procedures during
47 participants' clinic visits. Baseline and post intervention assessments will be carried out by the
48 blinded Medical Officers consulting at the study setting.
49
50
51
52
53
54
55
56
57
58
59
60

Phase 3: Qualitative evaluation of the PR intervention

Focus groups with patients

Participants allocated to the intervention group will be invited to participate in focus group discussions at the end of their PR programme. Focus groups will give an insight on views, experiences, opinions and recommendations which will inform future PR programmes. We anticipate conducting up to 5 focus groups until data saturation. Each focus group discussion will be conducted with 6-8 participants in each.

Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes, and will be conducted a trained moderator and a note-taker). Focus groups will be transcribed verbatim, with identifiable information removed. Consent will be obtained from participants prior to their involvement in focus groups.

Interviews with PR staff

Health care personnel involved in delivering PR will be invited to participate in in-depth interviews at the end of the study to discuss aspects of feasibility and acceptability, such as insights into barriers and facilitators to attendance, logistical barriers of running a PR programme and their views of patients' experiences of the intervention. We anticipate conducting up to 15 interviews, each expected to last approximately 15-60 minutes. Interviews will be audio-recorded and will be conducted face-to-face by a trained interviewer. Interviews will be transcribed verbatim, with identifiable information removed.

Book of testimonies and evaluation form

Participants within PR will be asked to log their experience of PR as they progress through the programme. This will be in the form of a PR log book accessible to participants before, during and after sessions, as well as a dedicated evaluation form which will be provided as supplementary material. Staff involved in PR will also receive the same evaluation form at the end of the study.

Sample characteristics

Basic demographics including age, sex, religion, nationality, marital status, age of leaving full-time education, education level, ethnicity, employment status, monthly income, lung health, smoking status (packs per year), biomass fuel exposure, primary respiratory diagnosis, time since diagnosis in years, secondary respiratory diagnoses, family history of lung disease, comorbidities will be recorded at baseline.

Lung function

Spirometry (post bronchodilator Forced Expiratory Volume in the first second (FEV₁), post bronchodilator Forced vital capacity (FVC), FEV₁/FVC ratio, carboxyhemoglobin test¹⁹, hospitalisations within the last 12 months, number of COPD exacerbations within the last 12 months, treatments will be collected as the baseline data prior to the randomisation of participants.

Nutritional status

Height (Holtain stadiometer), weight (calibrated weight scale) will be measured and body mass index will be calculated. Mid upper arm circumference of the participants will be measured using a measuring tape and skinfold thickness of seven sites (triceps, mid axillary, subscapular, chest, abdominal, supra iliac and thigh measurements) of the body will be measured using a validated caliper. Triplicated measurements will be taken by same investigator and mean value will be used for the calculation of body fat mass. Fat free mass will be calculated using Durnin and Womersley formula.^{20, 21} Body composition analysis will be assessed using bioelectrical impedance (SFB7 Impedi Med dual frequency instrument, Impedi Med Limited, Australia) and software version 5.2.4.0.²² Seven-day diet diary method will be used to assess the dietary history and calorie intake.

Disease burden

Breathlessness will be measured using MRC dyspnoea grade (5-items).²³ The health-related quality of life related to mobility, self-care, usual activities, pain/discomfort and anxiety-depression will be measured using EQ-5D-5L (25-items),²⁴ Clinical status of the airways, functional limitations and psychosocial dysfunction will be determined using CCQ (10 -items),²⁵

1
2
3 CAT (8-items) will be used to determine the severity of the COPD,²⁶ Modified brief pain
4 inventory (3-items) will determine the commonly reported chest pain, WPAI (8-items) will be
5 used to measure the effect of severity of COPD and general health on work productivity and
6 regular activities²⁷ and HADS (14-items) will be used to measure the patient's emotional state
7 and the presence or absence of clinically significant anxiety and depression.²⁸ Disease burden
8 will be measured as baseline data prior to the randomisation and post-intervention data.
9

14 Exercise capacity

15
16 Following a safety assessment for absolute and relative contraindications for field walking
17 tests²⁹, maximal exercise capacity will be assessed using the incremental shuttle walking test
18 (ISWT)³⁰ and endurance shuttle walking test (ESWT).¹⁸ The ISWT and ESWT also include a
19 pre-test and post-test measure of SpO₂, blood pressure, Borg rating of breathlessness³¹, heart
20 rate, Borg rate of perceived exertion.³² The sit-to stand test will be completed for five continuous
21 repetitions, to measure lower limb movement and strength.³³ All measures of exercise capacity
22 will be measured at baseline prior to the randomisation and post-intervention.
23
24
25
26
27
28

29 Accelerometry-derived physical behaviours

30
31 Participants will be asked to wear an activity monitor (ActiGraph wGT3X-BT, ActiGraph,
32 Pensacola, FL, USA), able to detect a range of PA intensities³⁴, on the right anterior hip during
33 waking hours for seven days prior to attending PR (baseline) and for the seven consecutive days
34 prior to their discharge assessment (follow-up); taking it off for water-based activities and sleep.
35 The collection of physical activity data will coincide with a 7-day diet diary. Printed instructions
36 will be provided to the participants regarding how to wear the monitor.
37
38
39
40
41
42

43 Full accelerometry methodology is provided in Table 3. Data will be processed as 60-s epoch
44 files in ActiLife version 6.13.4 (ActiGraph, Pensacola, FL, USA). Non-wear will be defined as
45 60-minutes of consecutive zero counts with allowance for 2-minutes of interruptions.³⁵

46 Adherence to wearing the monitors will be assessed by examining the proportion of participants
47 providing valid accelerometer data across a range of valid days ($\geq 1-7$ days) and minimum wear
48 time ($\geq 1-12$ hours) thresholds. For reported group averages, only participants providing ≥ 4 valid
49 days of ≥ 8 hours, for both time points will be included in the analyses.³⁶ Step count, time spent
50 in different absolute intensity classifications of physical behaviours³⁷ and average movement
51
52
53
54
55
56
57
58
59
60

intensity (activity counts per minute) will be reported. Time spent in physical activity matching participants' prescribed walking exercise intensity will be derived by aligning the average walking speed during the ESWT with the activity monitor counts per minute.

Table 3: Accelerometry data collection and processing parameters

Accelerometer Model	ActiGraph wGT3X-BT (version 6.13.4; firmware 1.9.2)
Serial number range	Twenty unique devices will be used ranging from MOS2E09190601 to MOS2E24190146 averaging six deployments per device (same serial used for baseline and follow-up wear periods)
Piezosensor orientation	Triaxial
Mode setup	Mode 29 (x, y, z, steps, lux)
Original sample rate	100 Hz (.gt3x file format)
Deployment method	Baseline: Fitted by research team on Day 0 (Baseline PR Assessment) Fitted by participant on Day 1 Follow-up: Fitted by research team Day 0 (11 th /12 th session) Fitted by participant on Day 1
Location worn	Anterior hip adjacent to the mid-line of the thigh
Requested days of wear	7 days of free-living (Day 1-7; 10,080 epochs)
Initialization	Not deployed in delay mode in order to standardised capture of Day 0 (00:00) with stop time based on date of first PR class (baseline) and data of discharge assessment (follow-up)
Wear instructions	Wear continuously except for sleep and water based activities
Non-wear appropriation	≥60 min of consecutive 0s with allowance for 2 minutes of interruptions were deemed biologically implausible and coded as non-wear
Valid day criteria	≥8 hours of valid waking wear time
Valid file	≥4 valid days for each of the two time points
Missing data	Data modelling or imputation will not be performed
Epoch length	60 seconds
Intensity classification (absolute)	Uniaxial (x-axis) cut-points as follows: Sedentary time <100 cpm; Light intensity 100-2019 cpm; Moderate intensity 2020-5998cpm; Vigorous intensity ≥5999cpm (Moderate-to-vigorous intensity ≥2020 cpm)
Intensity classification (relative)	Uniaxial (x-axis) cut-points based on Endurance Shuttle Walk Test performance

Costing

As part of this trial, the cost of creating a Sri-Lankan adapted PR programme will be calculated. This will include both single and recurrent costs. Single payments include the necessary costs to set up and run a programme, whilst recurrent cost refers to any item with a life expectancy of 1 year or less and typically includes disposable materials.³⁸ The fixed costs will be captured prior to the first participant enrolling into the programme and the recurrent costs will be collected at the mid-stage of recruitment. An average cost per participant will be calculated. Table 4 demonstrates the variables that will be used to calculate fixed and recurrent costs.

Table 4: The variables used to calculate fixed and recurrent costs (not an exhaustive list)	
Fixed costs	Recurrent costs
Venue hire	Venue hire
Electrical equipment (laptop, printer, projector)	Staff time to conduct PR (assessment at baseline and discharge, conduct PR classes, telephone calls and data entry)
Equipment for PR (weights, treadmill, cycle ergometer, country-specific equipment, step-up box, chairs)	Disposable equipment (for blood glucose monitor, spirometer mouthpieces, nose-clips, glyceryl trinitrate spray)
Equipment for shuttle walking tests (cones, licences, stop watches, tape measure, electrical equipment to play audio)	Servicing costs (spirometer, PR equipment, specifically treadmills and cycle ergometers)
Equipment for PR assessment (height stadiometer, weight scales, sphygmomanometer, pulse oximeter, spirometer, calibration syringe, country-specific equipment)	Miscellaneous (Oxygen cylinders, questionnaire licences, stationery (paper))
Additional safety equipment (blood glucose monitor, Oxygen cylinder holder)	
Miscellaneous (filing cabinets, storage units, questionnaire translations, questionnaire licences, staff uniform)	

Data management

Data collected during the study will be entered into a database using Research Electronic Data Capture (REDCap), which is a web-based platform.³⁹ Access to the database will be via a secure password protected web-interface. The participants will be identified by a study-specific identification code. Data will be validated using real-time data entry validation and electronic checks lead by the Independent Data Monitoring Committee (IDMC), established at the University of Leicester, UK.

Quantitative data analysis

The data will be analyzed using IBM SPSS Statistics for Windows, Version 23.0. Data for baseline and follow-up time-points will be presented as descriptive statistics as appropriate. No inferential statistics will be performed due to the feasibility design of the trial.

Qualitative data analysis

Qualitative data will be analyzed using Thematic Analysis. This approach follows six distinct stages: familiarization with data; generating initial codes; searching for themes; reviewing themes; defining and naming themes and producing the report.⁴⁰ The responsible investigator will carry out initial coding and a sample of focus group transcripts will be coded by a second member of the team to improve consistency and to enhance interpretive authenticity. Throughout the data analysis, the team will meet to discuss and review emerging themes and search the accounts that provide contesting views of the same phenomena. Close attention will be paid to the complexity and interactions inherent in the focus group data.⁴¹

Adverse events

All adverse events and serious adverse events will be recorded on an adverse event log, within study trial management paperwork, case report forms and REDCap. There will be no formal interim analysis of data due to the feasibility nature of the trial. The IDMC will review high level safety data. Adverse events will be monitored at least every month, and as needed on an ad hoc basis, to ensure the continuing safety of the participants. The Scientific Committee will determine the need to terminate the trial. Participant who experience any such event will be

1
2
3 directed to the appropriate hospital and all the necessary care will be ensured and followed-up
4 until the participant has resolved or stabilized.
5
6
7
8
9

10 **Ethics and dissemination**

11
12
13 Ethical approval will be obtained from the ethics review committee of the Faculty of Medical
14 Sciences, University of Sri Jayewardenepura and the University of Leicester, United Kingdom.
15 Further permission for the proposed study will be obtained from the relevant authority at the
16 Central Chest Clinic, Colombo, Sri Lanka.
17
18
19

20
21 Privacy and the confidentiality of all information and identities of participants will be strictly
22 maintained and will not be disclosed when publishing the results of the study.
23
24

25
26 A copy of the test results obtained will be provided to each participant at the end of the trial for
27 subsequent follow-up and treatment at the clinic. Compensation for travelling will be provided to
28 all the participants. All study documents have been translated to Sinhala and Tamil to ensure
29 clear communication. Participation will be without compulsion and each participant has the right
30 to withdraw at any time, without providing a reason. Consent form and data sheets will be
31 securely stored in a separate locked cupboard. Study computers will be password protected. All
32 the data will be stored safely up to 6 years and after 6 years consent form and data sheets will be
33 disposed of appropriately. Study team and IDMC only will have access to final trial dataset. Data
34 from the Global RECHARGE Core Dataset will be made available following the completion of
35 this project and we are considering the best tools to use to make this database available to the
36 wider community. Any modifications of the protocol will be updated on trial registry (ISRCTN)
37 and will be informed to the ethics review committee and the participants. Participants will be
38 provided the provisions for re-consenting after any change of the approved protocol. It will be
39 made clear in the publication of trial findings.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author affiliations

¹Faculty of Health Sciences, KAATSU International University, Sri Lanka

²Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University Hospitals of Leicester NHS Trust, UK

³Department of Respiratory Sciences, University of Leicester, Leicester, UK,

⁴Sports Medicine Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka

⁵Department of Nursing and Midwifery, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Sri Lanka

⁶National Hospital of Sri Lanka and Central Chest Clinic, Colombo, Sri Lanka

⁷Primary Care Respiratory Group, Sri Lanka

⁸Faculty of Health, University of Plymouth, UK

⁹School of Sport, Exercise and Health Sciences, Loughborough University, UK

¹⁰Department of Economics, University of Sheffield, Sheffield, UK

¹¹Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka

Author contribution All authors of the paper have contributed to the conception and design of the study. ARJ drafted the manuscript. All authors of the paper have revised the content and approved the final version to be published. All authors are accountable for all aspects of the work.

Funding This research was funded by the National Institute for Health Research (NIHR) (17/63/20) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Competing interests None declared.

References

1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J*. 2019;53(5).
2. Alwan A. Global Status Report on Non-Communicable Diseases. WHO, 2010
3. World Health Organization. Global surveillance, prevention and control of Chronic Respiratory Diseases, Switzerland, 2007; 22-23.
4. Amarasiri L, Fernando A, Gunasekara K, Gunasinghe W, Madegedara D, Wickramasinghe R. The prevalence of Chronic Obstructive Pulmonary Disease in Sri Lanka. *European Respiratory Journal*, 2017; 2017(50):1212.
5. World Health Organization. WHO strategy for prevention and control of chronic respiratory diseases, Geneva, 2017.
6. Yasaratne D, Dharmage SC. Letter from Sri Lanka. *Respirology*. 2020;25:339-41.
7. Pinnock H, Kendall M, Murray SA, Worth A, Levack P, Porter M, et al. Living and dying with severe chronic obstructive pulmonary disease: Multi-perspective longitudinal qualitative study. *BMJ*. 2011;342:268.
8. Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K. Comment Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs : challenges and opportunities. *Lancet Respir [Internet]*. 2019;7(12):1002-4.
9. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society Documents American Thoracic Society / European Respiratory Society Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med*. 2006;173(May):1390-413.
10. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease (Review). *Cochrane Database Syst Rev*. 2015;2015(2).
11. Jones AW, Taylor A, Gowler H, Kelly NO, Ghosh S, Bridle C. Systematic review of interventions to improve patient uptake and completion of pulmonary rehabilitation in COPD. *ERJ Open Res*. 2017;3.

12. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit 2013 statement: Defining standard protocol items for clinical trials. *Chinese J Evidence-Based Med.* 2013;13(12):1501–7.
13. Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults: accredited by NICE. *Thorax.* 2013;68:ii1-ii30.
14. Ries AL, Bauldoff GS, Casaburi R, Mahler DA, Rochester CL, Herrerias C. Pulmonary Rehabilitation; Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest.* 2007;131(5):4S-42S.
15. Blackstock FC, Evans RA. Rehabilitation in lung diseases: ‘Education’ component of pulmonary rehabilitation. *Respirology.* 2019;24(9):863–70
16. Spencer LM, McKeough ZJ. Maintaining the benefits following pulmonary rehabilitation: Achievable or not? *Respirology.* 2019;24(9):909–15.
17. Armstrong M, Vogiatzis I. Personalized exercise training in chronic lung diseases. *Respirology.* 2019;24(9):854–62.
18. Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk : a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. *Thorax.* 1999;54(2):213–22
19. Yasuda H, Yamaya M, Nakayama K, Ebihara S, Sasaki T, Okinaga S, et al. Increased Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2005;171:1246–51.
20. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 Years. *Br J Nutr.* 1974;32:77–96.
21. Doña E, Oliveira C, Palenque FJ, Porras N, Dorado A, Martín-valero R, et al. Body Composition Measurement in Bronchiectasis: Comparison between Bioelectrical Impedance Analysis, Skinfold Thickness Measurement, and Dual-Energy X-ray Absorptiometry before and after Pulmonary Rehabilitation. *J Acad Nutr Diet.* 2018;118(8):1464–73.
22. Lanerolle MD, Lanerolle P, Atukorala S, Silva A De. Enhancing the accuracy of bio impedance analysis in assessing total body water. *Int J Body Compos Res.* 2012;10(1):29–34.
23. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with

- 1
2
3 chronic obstructive pulmonary disease. *Thorax*. 1999;54:581–6.
4
5 24. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
6 preliminary testing of the new five-level version of EQ-5D (EQ-5D5L). *Quality of Life*
7 *Research*. 2011;20(10): 1727-736.
8
9
10 25. Van der Molen T, Willemse BW, Schokker S, et al. Development, validity and
11 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes*. 2003;1:13.
12
13 26. Papaioannou M, Pitsiou G, Manika K, Kontou P, Zarogoulidis P, Sichletidis L, Kioumis IP.
14 COPD assessment test: A simple tool to evaluate disease severity and response to treatment.
15 *J of Chronic Obstructive Pulmonary Disease*. 2014;11:489- 95.
16
17 27. Reilly MC, Zbrozek IAS, Dukes EM. The Validity and Reproducibility of a Work
18 Productivity and Activity Impairment Instrument. *Pharmacoeconomics*. 1993;4(5):353–65.
19
20 28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica*
21 *Scandinavica*. 1983;67(6):361-70.
22
23 29. Weisman IM, Marciniuk D, Martinez FJ, Sciurba F, Sue D, Myers J, et al. American
24 Thoracic Society / American College of Chest Physicians ATS / ACCP Statement on
25 Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med*. 2003;167:211–77.
26
27 30. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking
28 test of disability in patients with chronic airways obstruction. *Thorax*. 1992;47(12):1019-24.
29
30 31. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with
31 respiratory disease. *Med Sci Sports Exerc*. 1994;26:1078–1081.
32
33 32. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14:377–
34 381
35
36 33. Jones SE, Kon SSC, Canavan JL, Patel MS, Clark AL, Nolan CM, et al. The five-repetition
37 sit-to-stand test as a functional outcome measure in COPD. *Thorax*. 2013;68:1015–20.
38
39 34. Bassett DR, John D. Use of pedometers and accelerometers in clinical populations: validity
40 and reliability issues. *Phys Ther Rev*. 2010;15:135–42.
41
42 35. Choi L, Liu Z, Matthews CE, Buchowski MS. Validation of accelerometer wear and nonwear
43 time classification algorithm. *Med Sci Sports Exerc*. 2011;43:357–64.
44
45 36. Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, et al.
46 Standardizing the analysis of physical activity in patients with COPD following a pulmonary
47 rehabilitation program. *Chest* 2014 Aug;146(2):318-327
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 37. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in
4 the United States measured by accelerometer. *Med Sci Sports Exerc* 2008 Jan;40(1):181-188.
5
6 38. Lucas AO, Gilles HM. Approaches to economic evaluation. *Short Textbook of Public Health*
7 *Medicine for the Tropics*. 2002. CRC Press.
8
9 39. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap
10 consortium: Building an international community of software platform partners. *J Biomed*
11 *Inform*. 2019;95.
12
13 40. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3:77–101
14
15 41. Maguire M, Delahunt B. Doing a Thematic Analysis : A Practical, Step-by-Step Guide for
16
17 Learning and Teaching Scholars. *AISHE-J*. 2017;8(3):3351–14.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Primary outcome measures- Feasibility and operational experience assessment

Feasibility of patient recruitment	Data sources
Feasibility of screening and recruiting participants	Interviews with the healthcare professionals, screening log
Suitability of the inclusion criteria	Interviews with the healthcare professionals, screening log
Number of eligible patients, number of patients screened, number of patients invited to take part, actual number of participants who consent to take part	Screening log
Number of patients who refuse, drop out and the reasons for refuse and drop out	Interviews with the patients, screening log
Operational experience of intervention delivery	
Service provider and multi-disciplinary teams' willingness and ability to deliver the PR	Interviews with healthcare professionals
The practicality of delivering the intervention in the proposed setting	Interviews with healthcare professionals and focus groups with participants
The time needed to collect the data Baseline visit- Time taken for each measure (each individual questionnaire and physical measure) Follow-up visit- Time taken for each measure (each individual questionnaire and physical measure)	Interviews with the healthcare professionals, Rehabilitation records
Data completeness and accuracy	Interviews with the healthcare professionals, Rehabilitation records, RedCap
Adherence to home exercise	Interviews with the patients and self-report exercise diary
The training and resources needed to deliver the intervention (ensuring readiness for a future much larger multi-center trial)	Interviews with the healthcare professionals and focus groups with participants, Rehabilitation records
Description of unintended events	Adverse events log, REDCap

Table 2: Secondary outcome measures

Outcome measures	Baseline	Post-intervention
Socio-demographics	x	
Lung health (spirometry data, smoking status, number of COPD exacerbations in the last year)	x	
Comorbidities	x	
Treatments	x	
Nutritional status (Body Mass Index, mid upper arm circumference, skinfold thickness, self-report seven-day diet diary)	x	x
Disease burden (MRC dyspnea grade, CAT, CCQ)	x	x
Economic impact of disease (WPAI)	x	x
Quality of life (EQ-5D-5L)	x	x
Psychological wellbeing (Hospital Anxiety and Depression scale)	x	x
Physical function (5x sit-to-stand test)	x	x
Exercise capacity (ISWT, ESWT)	x	x
Accelerometer assessed physical activity (ActiGraph wGT3x-BT)	x	x

Table 3: Accelerometry data collection and processing parameters

Accelerometer Model	ActiGraph wGT3X-BT (version 6.13.4; firmware 1.9.2)
Serial number range	Twenty unique devices will be used ranging from MOS2E09190601 to MOS2E24190146 averaging six deployments per device (same serial used for baseline and follow-up wear periods)
Piezosensor orientation	Triaxial
Mode setup	Mode 29 (x, y, z, steps, lux)
Original sample rate	100 Hz (.gt3x file format)
Deployment method	Baseline: Fitted by research team on Day 0 (Baseline PR Assessment) Fitted by participant on Day 1 Follow-up: Fitted by research team Day 0 (11 th /12 th session) Fitted by participant on Day 1
Location worn	Anterior hip adjacent to the mid-line of the thigh
Requested days of wear	7 days of free-living (Day 1-7; 10,080 epochs)
Initialization	Not deployed in delay mode in order to standardised capture of Day 0 (00:00) with stop time based on date of first PR class (baseline) and data of discharge assessment (follow-up)
Wear instructions	Wear continuously except for sleep and water based activities
Non-wear appropriation	≥ 60 min of consecutive 0s with allowance for 2 minutes of interruptions were deemed biologically implausible and coded as non-wear
Valid day criteria	≥ 8 hours of valid waking wear time
Valid file	≥ 4 valid days for each of the two time points
Missing data	Data modelling or imputation will not be performed
Epoch length	60 seconds
Intensity classification (absolute)	Uniaxial (x-axis) cut-points as follows: Sedentary time < 100 cpm; Light intensity 100-2019 cpm; Moderate intensity 2020-5998cpm; Vigorous intensity ≥ 5999 cpm (Moderate-to-vigorous intensity ≥ 2020 cpm)
Intensity classification (relative)	Uniaxial (x-axis) cut-points based on Endurance Shuttle Walk Test performance

Table 4: The variables used to calculate fixed and recurrent costs (not an exhaustive list)

Fixed costs	Recurrent costs
Venue hire	Venue hire
Electrical equipment (laptop, printer, projector)	Staff time to conduct PR (assessment at baseline and discharge, conduct PR classes, telephone calls and data entry)
Equipment for PR (weights, treadmill, cycle ergometer, country-specific equipment, step-up box, chairs)	Disposable equipment (for blood glucose monitor, spirometer mouthpieces, nose-clips, glyceryl trinitrate spray)
Equipment for shuttle walking tests (cones, licences, stop watches, tape measure, electrical equipment to play audio)	Servicing costs (spirometer, PR equipment, specifically treadmills and cycle ergometers)
Equipment for PR assessment (height stadiometer, weight scales, sphygmomanometer, pulse oximeter, spirometer, calibration syringe, country-specific equipment)	Miscellaneous (Oxygen cylinders, questionnaire licences, stationery (paper))
Additional safety equipment (blood glucose monitor, Oxygen cylinder holder)	
Miscellaneous (filing cabinets, storage units, questionnaire translations, questionnaire licences, staff uniform)	




Figure 1: Flow of participant of the three phases of the study

Appendices

Information sheet

Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

I am Prof. S. W. Wimalasekera, of Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura. I and my team of health care personnel are, conducting a research on “Testing the Feasibility and Acceptability of a Culturally Appropriate Hospital-Based Pulmonary Rehabilitation (PR) Programme for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka”. I invite you to participate in the study. Please take time and read the following information carefully before giving your consent. You are free to ask questions to clarify facts which are not clear or ask for more information if you need.

Purpose of the study

The purpose of this study is to devise an appropriate PR programme and then determine the feasibility and acceptability of this programme for adults living with COPD in Sri Lanka and assess the potential for a future trial of its effectiveness.

When you participate you will be required to do the following

You will be requested to participate several components of the study.

You will participate in a group discussion conducted in a quiet room in the clinic (conference hall) with very minimal disturbances. At the beginning of the discussion you will answer some questions regards your personal information, (age, gender, history of the disease condition). Then the interviewer will ask some questions regarding your thoughts and ideas about pulmonary rehabilitation. You and your group members can freely comment on the questions or can add your ideas to the discussion. The interview takes around forty-five minutes of time.

You will also participate in a feasibility trial which you will be allocated to one of the two groups. One group will receive usual care and PR and the other group will receive only usual care which consists of pharmacological treatment and brief information about disease condition, medication and inhaler techniques. PR is typically a 6-week rolling programme and consisting of 12 sessions in total, delivered twice a week. Sessions usually last approximately two hours, with one hour for exercise training and one hour for education. Some routine and specific test and measurements will be taken before and after the intervention will describe any changes in the health of the adults living with COPD.

If you are allocated to the group who receive the PR, you will be asked to share your experiences regarding the PR and subjected modification and opinions on pulmonary rehabilitation.

In order to maintain accuracy, and to keep records, your discussion will be recorded by the research team members with your permission. Your participation in the project will remain confidential and the provision of your name and address is necessary for us to maintain records. Any personal information gathered during the study will not be disclosed to a third party. Your responses to the questions and will

1
2
3 only be used for the purpose of this project. You can be assured that you will remain anonymous if you
4 take part in the project. Your participation in this project is entirely voluntary. You are not obliged to take
5 part. If you do not wish to take part, you can withdraw without giving a reason and your medical care will
6 not be affected, further you will not be contacted again. Similarly, if you do agree to participate, you are
7 free to withdraw at any time during the project.
8
9
10

11 **What are the possible benefits of taking part?**

12
13 By participating in the study, you will contribute to develop a PR programme which helps to improve the
14 quality of life of the adults living with COPD. As well as you will contribute to determine the feasibility
15 and acceptability of this programme within the health care system in Sri Lanka.
16
17
18

19 **What are the possible disadvantages and risks of taking part?**

20
21 You will be undertaking some physical tests as part of the research. Therefore, there may be a very small
22 risk of falls, breathlessness, changes in blood pressure and changes in heart rate. However, these risks are
23 very rare, and trained staff and emergency equipment will be available to deal with any serious events.
24 Participants who experience any such event will be directed to the appropriate hospital and all the
25 necessary care will be ensured and followed-up until the participant has resolved or stabilized.
26
27
28

29 **What will happen if you don't carry on with the study?**

30
31 If you withdraw from the study all the information and data collected from you, to date, will be destroyed
32 and your name would be removed from all the research study files. There will not be any loss or impact
33 on your routine medical care which you are entitled to.
34
35
36

37 **What will happen to the results of the research study?**

38
39 The results of all the participants of the study will be used for scientific research. All data will be
40 available only to the researchers and information provided will be strictly confidential. Your participation
41 in the study is highly appreciated. Privacy and confidentiality of data gathered is completely secure and
42 will be used only for research purposes. If you have any questions or any concerns with regards to the
43 study and need further information you can call the telephone number listed below. Further you can send
44 any complaint to the above postal address or email address.
45
46
47

48 Yours faithfully

49 Prof. S.W. Wimalasekera

50 Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura

51 T.P No. 0777487203 e-mail : savithriww@yahoo.com

52 Ethics Review Committee – University of Sri Jayewardenepura - +94 11 2758000 Ext 4075e
53
54
55
56
57
58
59
60

1
2
3 **Consent Form: Randomised Controlled Feasibility Trial**
4

5 **Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised**
6 **Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka**
7

- 8 1. Have you read the information sheet? (please keep a copy for yourself) YES/NO
9
10 2. Have you had an opportunity to discuss this and ask any questions? YES/NO
11
12 3. Have you had satisfactory answers to all your questions? YES/NO
13
14 4. Have you received enough information about the study? YES/NO
15
16 5. Who explained the study to you-----
17
18 6. Do you understand that you are free to withdraw from the study at any time,
19 without having to give a reason YES/NO
20
21 7. All personal details will be treated as STRICTLY CONFIDENTIAL.
22 Do you give your permission for these individuals to have access to the records? YES/NO
23
24 8. Have you had sufficient time to come to your decision? YES/NO
25
26 9. Do you agree to take part in this study? YES/NO

27 Participant's signature ----- Date-----
28
29
30

31 **By the Witness**
32

33 I have been present while the procedure was explained to the participant and I have witness his/ her
34 willingness to take part in the study.
35

36 Signature of witness----- Date-----
37

38 (The witness should be a person not connected to the study)
39

40 Name -----
41

42 Contact details-----
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page(s)
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	01
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	02
	2b	All items from the World Health Organization Trial Registration Data Set	01 - 19
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	19
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	01,18
	5b	Name and contact information for the trial sponsor	19
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	19
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	17
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	03
	6b	Explanation for choice of comparators	NA
Objectives	7	Specific objectives or hypotheses	04
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	04

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	05
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	05
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	07
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	17.18
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	09, 18
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	18
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	08 - 10
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	06
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	07

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
---------------------	-----	--	----

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	10
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	10
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	10, 11
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13		17b	If blinded, circumstances under which unblinding is permissible, and	NA
14			procedure for revealing a participant's allocated intervention during	
15			the trial	
16				
17				
18				
19				

Methods: Data collection, management, and analysis

20				
21				
22	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	11 - 15
23	methods		trial data, including any related processes to promote data quality (eg,	
24			duplicate measurements, training of assessors) and a description of	
25			study instruments (eg, questionnaires, laboratory tests) along with	
26			their reliability and validity, if known. Reference to where data	
27			collection forms can be found, if not in the protocol	
28		18b	Plans to promote participant retention and complete follow-up,	07
29			including list of any outcome data to be collected for participants who	
30			discontinue or deviate from intervention protocols	
31				
32				
33				
34	Data	19	Plans for data entry, coding, security, and storage, including any	17
35	management		related processes to promote data quality (eg, double data entry;	
36			range checks for data values). Reference to where details of data	
37			management procedures can be found, if not in the protocol	
38				
39				
40	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	17
41	methods		Reference to where other details of the statistical analysis plan can be	
42			found, if not in the protocol	
43		20b	Methods for any additional analyses (eg, subgroup and adjusted	17
44			analyses)	
45		20c	Definition of analysis population relating to protocol non-adherence	17
46			(eg, as randomised analysis), and any statistical methods to handle	
47			missing data (eg, multiple imputation)	
48				
49				
50				
51				

Methods: Monitoring

52				
53				
54	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	17
55			and reporting structure; statement of whether it is independent from	
56			the sponsor and competing interests; and reference to where further	
57			details about its charter can be found, if not in the protocol.	
58			Alternatively, an explanation of why a DMC is not needed	
59				
60				

1				
2		21b	Description of any interim analyses and stopping guidelines, including	17
3			who will have access to these interim results and make the final	
4			decision to terminate the trial	
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and	17
7			spontaneously reported adverse events and other unintended effects	
8			of trial interventions or trial conduct	
9				
10				
11	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	17
12			whether the process will be independent from investigators and the	
13			sponsor	
14				
15				
16	Ethics and dissemination			
17	Research ethics	24	Plans for seeking research ethics committee/institutional review board	18
18	approval		(REC/IRB) approval	
19				
20	Protocol	25	Plans for communicating important protocol modifications (eg,	18
21	amendments		changes to eligibility criteria, outcomes, analyses) to relevant parties	
22			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
23			regulators)	
24				
25				
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial	7
27			participants or authorised surrogates, and how (see Item 32)	
28				
29		26b	Additional consent provisions for collection and use of participant data	NA
30			and biological specimens in ancillary studies, if applicable	
31				
32	Confidentiality	27	How personal information about potential and enrolled participants will	18
33			be collected, shared, and maintained in order to protect confidentiality	
34			before, during, and after the trial	
35				
36				
37	Declaration of	28	Financial and other competing interests for principal investigators for	19
38	interests		the overall trial and each study site	
39				
40	Access to data	29	Statement of who will have access to the final trial dataset, and	18
41			disclosure of contractual agreements that limit such access for	
42			investigators	
43				
44				
45	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	17,18
46	post-trial care		compensation to those who suffer harm from trial participation	
47				
48	Dissemination	31a	Plans for investigators and sponsor to communicate trial results to	01
49	policy		participants, healthcare professionals, the public, and other relevant	
50			groups (eg, via publication, reporting in results databases, or other	
51			data sharing arrangements), including any publication restrictions	
52				
53				
54		31b	Authorship eligibility guidelines and any intended use of professional	19
55			writers	
56				
57		31c	Plans, if any, for granting public access to the full protocol, participant-	18
58			level dataset, and statistical code	
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	See Appendix
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

Protocol for the Cultural Adaptation of Pulmonary Rehabilitation and Subsequent Testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041677.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Oct-2020
Complete List of Authors:	<p>Jayamaha, Akila; KIU, Health Sciences Perera, Chamilya; KIU, Health Sciences Orme, Mark; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Jones , Amy; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Wijayasiri, Upendra; Colombo South Teaching Hospital, Sports Medicine Unit Amarasekara, Thamara; University of Sri Jayewardenepura, Faculty of Allied Health Sciences Karunatilake, Ravini ; National Hospital of Sri Lanka, Central Chest Clinic Fernando, Amitha; National Hospital of Sri Lanka, Central Chest Clinic Seneviratne, Anthony ; Primary Care Respiratory Group Barton, Andy; University of Plymouth, Faculty of Health Jones, Rupert; University of Plymouth, Faculty of Health Yusuf, Zainab; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University Hospitals of Leicester NHS Trust; University of Leicester, Department of Respiratory Sciences Miah, Ruhme ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory Malcolm, Dominic; Loughborough University, School of Sport, Exercise and Health Sciences Matheson, Jesse; University of Sheffield, Department of Economics Free, Robert; University of Leicester, Department of Respiratory Sciences, Manise, Adrian ; University of Leicester, Department of Respiratory Sciences Steiner, michael ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory</p>

	Wimalasekera, Savithri; University of Sri Jayewardenepura, Faculty of Medical Sciences Singh, Sally; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory
Primary Subject Heading :	Respiratory medicine
Secondary Subject Heading :	Rehabilitation medicine
Keywords :	REHABILITATION MEDICINE, Chronic airways disease < THORACIC MEDICINE, Emphysema < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Protocol for the Cultural Adaptation of Pulmonary Rehabilitation and Subsequent Testing**
5
6 2 **in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive**
7
8 3 **Pulmonary Disease in Sri Lanka**
9

10 4 Akila R Jayamaha ¹, Chamilya H Perera ¹, Mark W Orme ^{2,3}, Amy V Jones ^{2,3}, Upendra K D C Wijayasiri
11 5 ⁴, Thamara D Amarasekara ⁵, Ravini de S Karunatillake ⁶, Amitha C Fernando ⁶, Seneviratne A L P De
12 6 S.⁷, Andy Barton ⁸, Rupert Jones ⁸, Zainab K Yusuf ^{2,3}, Ruhme B Miah ^{2,3}, Dominic Malcolm ⁹, Jesse A
13 7 Matheson ¹⁰, Robert C Free ³, Adrian Manise ³, Michael C Steiner ^{2,3} Savithri W Wimalasekera ¹¹, Sally J
14 8 Singh ^{2,3}
15 9

16 10 Correspondence to Akila Randika Jayamaha/1226arj@gmail.com/akila@kiu.ac.lk
17

18 11 **Abstract**
19

20
21 12 **Introduction** International guidelines recommend pulmonary rehabilitation (PR) should be
22
23 13 offered to adults living with COPD, but there is limited PR available in Sri Lanka. Culturally
24
25 14 appropriate PR needs to be designed and implemented in Sri Lanka. The study aims to adapt PR
26
27 15 to the Sri Lankan context and determine the feasibility of conducting a future trial of the adapted
28
29 16 PR in Sri Lanka.

30
31 17 **Methods and analysis** Phase-1: Develop the intervention: Focus groups with adults living with
32
33 18 COPD, caregivers and nurses and in-depth interviews with doctors and physiotherapist will be
34
35 19 conducted to inform PR adaptations. Phase-2: Randomised controlled feasibility trial will be
36
37 20 conducted in Central Chest Clinic, Colombo, Sri Lanka. Eligible participants will be identified
38
39 21 and will be invited to take part. A total of 50 participants will be recruited to the trial and
40
41 22 randomised (1:1) into one of two groups; control group receiving usual care or the intervention
42
43 23 group also receiving PR. The PR programme is likely to consist of 12 sessions of exercises and
44
45 24 health education, delivered over 6 weeks. After completion of PR, routine measures in both
46
47 25 groups will be assessed by a blinded assessor. The primary outcome measure is feasibility,
48
49 26 including assessing eligibility, uptake and completion. Phase-3: Qualitative evaluation of the
50
51 27 trail: Focus groups with participants and in-depth interviews with PR deliverers will be
52
53 28 conducted to further determine feasibility and acceptability of PR, as well as ability to run a
54
55 29 larger trial.

56 30 **Ethics and dissemination** Ethical approval was obtained from the ethics review committee of
57
58 31 the Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and the
59

1
2
3 32 University of Leicester, UK. The results of the trial will be disseminated through patient and
4
5 33 public involvement events, local and international conference proceedings, and peer-reviewed
6
7 34 journals.

8
9 35 Trial registration: ISRCTN13367735

10
11 36 **Keywords:** COPD, Pulmonary Rehabilitation, Exercise, Education, Sri Lanka
12
13 37

14 38
15 39 **Strengths and limitations**

- 16
17 40 • This study is the first examining the feasibility and acceptability of a culturally
18
19 41 appropriate pulmonary rehabilitation programme for adults with COPD in Sri Lanka.
20
21 42 • Taking a mixed-method approach, this study will provide a rich insight into delivering a
22
23 43 trial of pulmonary rehabilitation in the Sri Lankan context.
24
25 44 • This study is a single center feasibility trial. As such, whilst findings will be an important
26
27 45 first step in understanding the potential role of pulmonary rehabilitation in Sri Lanka and
28
29 46 low- and middle-income countries more broadly, findings may not be generalizable to
30
31 47 other regions of the world.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 INTRODUCTION

49 Chronic obstructive pulmonary disease (COPD) is a progressive disease characterised by airflow
50 obstruction and breathlessness. COPD is a major cause of morbidity and mortality throughout the
51 world, corresponding to 6% of all deaths worldwide.¹ Further, more than 90% of COPD deaths
52 occur in low and middle-income countries.² The most recent estimate of COPD prevalence in
53 South Asia was 6.3%³ with a prevalence in Sri Lanka of 10.5%,⁴ similar to the estimated global
54 COPD prevalence of 11.7%.⁵ COPD is a significant burden to both patients and healthcare
55 services.⁶

56 Chronic cough with sputum, breathlessness, physical inactivity and exercise intolerance resulting
57 from dyspnoea or fatigue are common consequences of COPD.¹ Symptoms of COPD
58 progressively worsen and people can become breathless, even at rest. Daily activities often
59 become difficult as the condition worsens, impacting their quality of life.⁷ The impact of COPD
60 to the individual and to society makes the need for interventions to reverse the associated
61 disability of paramount importance.

62 International guidelines recommend that pulmonary rehabilitation (PR) should be routinely
63 offered to patients with chronic respiratory disease who have persistent symptoms, limited
64 activity, and/or are unable to adjust to illness.^{8,9} It is a low cost, high impact intervention that
65 improves the quality of life, reduces suffering, reduces mortality and reduces economic loss,
66 relieves dyspnoea and fatigue, improves exercise capacity, improves psychological and
67 emotional function, and enhances an individual's self-management of their condition.¹ Having
68 realised the benefits of PR in COPD, Western countries have incorporated this as an important
69 structural component of healthcare delivery services.¹⁰ Implementation of PR based as practiced
70 in Western countries, in Sri Lanka requires adaptation to the local health service, population and
71 culture. Despite its effectiveness, there is a significant need to understand the feasibility of
72 conducting PR in low resource Sri Lankan health care setting and the acceptability of PR among
73 Sri Lankan adults living with COPD and healthcare staff involved in its delivery. Uptake and
74 completion of PR even in Western countries is an on-going challenge.¹¹ The need to maximize
75 appeal of PR to patients and referrers is a global issue and one that is likely to be specific to a
76 given location and population. There remains an unmet need for PR in Sri Lanka. To be

1
2
3 77 successful, PR must be not only evidence-based, but also designed and implemented in a manner
4 78 sensitive to the context in which it is being delivered, such as culture and geography. Therefore,
5 79 the aim of this study is to devise an appropriate PR programme and then determine the feasibility
6 80 and acceptability of this programme for adults living with COPD in Sri Lanka and assess the
7 81 potential for a future trial of its effectiveness.

11
12
13 82 The objectives of the study are to:

- 14
15 83 1. Explore the needs and perceptions of adults living with COPD, their care-givers /family
16 84 members and health care professionals to inform the adaptations required for a PR programme
17 85 suitable for the Sri Lankan context.
18
19 86 2. Determine the feasibility of conducting adapted hospital-based PR for people living with
20 87 COPD.
21
22 88 3. Assess the acceptability of the PR among Sri Lankan adults living with COPD and healthcare
23 89 staff involved in its delivery.
24
25 90 4. Describe any changes in health of the adults living with COPD following completion of PR.
26
27 91 5. Assess the feasibility of a future trial and estimate the required sample size.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

93 **METHODS AND ANALYSIS**

94 **Study design and registration**

95 The proposed study will be conducted in three phases. Phase 1: A qualitative study will be
96 conducted to inform the adaptations required to make PR specific to the Sri Lankan context.
97 Phase 2 is a single blind randomised control feasibility trial. Adults living with COPD will be
98 randomised (1:1) into adapted PR or usual care. Phase 3: Qualitative evaluation of the trial to
99 determine the feasibility and acceptability of PR deliverers and participants. The trial will be
100 conducted, analysed and reported according to the Standard Protocol Items: Recommendations
101 for Interventional Trials (SPIRIT) statement ¹² and trial has been registered on the ISRCTN
102 website. Study was commenced upon ethical approval on 24/07/2020 for Phase 1 of the study.
103 The design of the study and flow of participant enrolment is presented in figure 1.

104 **Study setting**

105 The study will be carried out at the Central Chest Clinic, Colombo, Sri Lanka which is a leading
106 health care facility that provides treatment for adults with respiratory disease. A room allowing
107 confidential discussions will be used for conducting focus group discussions among adults living
108 with COPD, their caregivers /family members, and nurses. Semi structured interviews will be
109 conducted among doctors and physiotherapists in a given quiet room at the Central Chest Clinic
110 as convenient to them and without interfering with their routine work. The venue for PR will be a
111 large room at the Central Chest Clinic.

112 **Participants**

113 Key informants and suitable participants for phase 1 of the study will be identified by the
114 researchers with the help of health care professionals involved in the treatment of COPD at
115 Central Chest Clinic. Suitable participants will be purposively selected and informed verbally
116 about the study by the researchers. After receiving a study information sheet, potential
117 participants will be contacted to arrange an appointment, if they wish to take part. An
118 opportunity to ask questions will be provided. If willing to take part in the study, they will be
119 asked to provide written informed consent. Multi-religious and multi-ethnic Sri Lankan cultural
120 diversity and gender will be considered when recruiting to the study. Adults living with COPD
121 aged ≥ 18 years and Medical Research Council (MRC) dyspnoea score grade 2 or higher, Family
122 member aged ≥ 18 years and looks after a patient with COPD and Health care professionals who
123 have more than 1-year experience of managing patients with COPD and working in the
124 government health care system of the country will be eligible to participate in the phase 1 of the
125 study. Participants who provide written informed consent will be enrolled in the study.

126 After the adaptation of PR in phase 1, suitable participants for the Phase 2 randomised controlled
127 feasibility trial will be identified by the Medical Officers in the Chest Clinic and will be invited
128 to take part in an eligibility assessment. This assessment will determine eligibility for entry into
129 the study. People eligible for inclusion in the trial will be: aged ≥ 18 years, will have a clinically
130 confirmed diagnosis of COPD by a physician, confirmed COPD with spirometry based on
131 GOLD criteria with $FEV_1/FVC < 0.7$, and $FEV_1 < 80\%$ predicted, ≥ 1 exacerbation required a
132 hospitalisation in the year preceding study, mMRC grade ≥ 2 and willing to provide informed
133 consent. Adults with comorbidities such as severe or unstable cardiovascular, other internal

1
2
3 134 diseases and locomotor difficulties that preclude the exercise or malignant disease or other
4
5 135 serious illness which will interfere with participation in the PR, will be excluded from the study.
6
7 136 Individuals not eligible for the study will be recorded on a study screening log.

8
9 137 [insert figure 1 here]
10
11 138

14 139 **Procedure**

16
17 140 Eligible participants will be informed verbally about the study by the Medical Officers of the
18
19 141 Central Chest Clinic. After receiving a study information sheet, potential participants will be
20
21 142 contacted to arrange an appointment, if they wish to take part. An opportunity to ask questions
22
23 143 will be provided. If willing to take part in the study, they will be asked to provide written
24
25 144 informed consent. Information regarding the interest of participation in the study will be taken as
26
27 145 field notes. Baseline outcome measures will be assessed. After baseline data collection,
28
29 146 participants will be randomised (1:1) into two groups. One group will receive usual care and PR
30
31 147 and the other group will receive only usual care which consists of pharmacological treatment and
32
33 148 brief information about disease condition, medication and inhaler techniques. Experiences of the
34
35 149 participants and PR deliverers regarding the acceptability and feasibility of PR will be explored
36
37 150 in interviews and focus groups during Phase 3 of the study. Participants who did not complete
38
39 151 the PR will be asked to take part in a drop-out interview and information provided freely by the
40
41 152 participants will be collected as field notes.

40 153

41 154 **Trial interventions**

42 155 **Intervention: Adapted pulmonary rehabilitation**

43
44 156 Sri-Lankan specific PR will comprise the core elements of an evidence based rehabilitation, a
45
46 157 programme of exercises^{13, 14} and health education.^{13, 14, 15} The detail of delivery and adaptations
47
48 158 of PR will be informed by findings of the Phase 1 of the study. PR is typically a 6-week rolling
49
50 159 programme that consists of 12 sessions in total.^{13, 14} Sessions usually last approximately two
51
52 160 hours, with one hour for exercise training and one hour for education. All the education sessions
53
54 161 and the instructions during PR will be provided in Sinhala language as convenient to the
55
56 162 participants. The duration of the PR trial and frequency and duration of sessions will be

1
2
3 163 discussed during Phase 1. All staff delivering PR will be trained and assisted by a nursing
4 164 officer, a clinical nutritionist, an exercise physician and a physiotherapist. The venue for PR will
5 165 be at the Central Chest Clinic, Colombo, Sri Lanka. The Central Chest Clinic will have a
6 166 maximum capacity of 10 patients per PR class. The equipment required will be simple and
7 167 include chairs, weights, and simple exercise equipment based on local availability, suitability and
8 168 informed by qualitative work.¹⁶

13 169
14
15 170 In keeping with evidence-based guidelines^{13, 14}, discussions in Phase 1 will include the core
16 171 exercise component of PR, notably resistance training (e.g. upper and lower limbs) and aerobic
17 172 training (walking, sit-to-stand, step-ups) using minimal equipment and education. Each
18 173 participant's exercise regimen will be individually prescribed and progressed¹⁷ with walking
19 174 speed will be prescribed using the ISWT.¹⁸ The process in which this is achieved by patients will
20 175 be informed by Phase 1. The education component will be delivered by an interdisciplinary team
21 176 and will be informed by qualitative findings from Phase 1 with discussions facilitated by usual
22 177 education topics as described in guidelines.^{13, 14}

30 178 **Usual care**

31
32 179 Usual care will consist of pharmacological treatment and optimization, prescribed to patients
33 180 after consultation with Medical Officers at the Central Chest Clinic. Brief information about
34 181 disease condition, medication and inhaler techniques will be provided by Medical Officers and
35 182 Nurses. Pulmonary rehabilitation or any form of exercise recommendation is not part of usual
36 183 care.

42 184 **Outcomes**

45 185 **Primary outcome**

46
47 186 The primary outcome of the trial will be the feasibility and the acceptability of the PR
48 187 intervention.

52 188 **Feasibility**

189 Measures to assess feasibility are provided in table 1 and include the comprehensive assessment
 190 of the feasibility of patient recruitment and the intervention delivery.

Table 1: Primary outcome measures- Feasibility and operational experience assessment	
Feasibility of patient recruitment	Data sources
Feasibility of screening and recruiting participants	Interviews with the healthcare professionals, screening log
Suitability of the inclusion criteria	Interviews with the healthcare professionals, screening log
Number of eligible patients, number of patients screened, number of patients invited to take part, actual number of participants who consent to take part	Screening log
Number of patients who refuse, drop out and the reasons for refuse and drop out	Interviews with the patients, screening log
Operational experience of intervention delivery	
Service provider and multi-disciplinary teams' willingness and ability to deliver the PR	Interviews with healthcare professionals
The practicality of delivering the intervention in the proposed setting	Interviews with healthcare professionals and focus groups with participants
The time needed to collect the data Baseline visit- Time taken for each measure (each individual questionnaire and physical measure) Follow-up visit- Time taken for each measure (each individual questionnaire and physical measure)	Interviews with the healthcare professionals, Rehabilitation records
Data completeness and accuracy	Interviews with the healthcare professionals, Rehabilitation records, RedCap
Adherence to home exercise	Interviews with the patients and self-report exercise diary
The training and resources needed to deliver the intervention (ensuring readiness for a future much larger multi-center trial)	Interviews with the healthcare professionals and focus groups with participants, Rehabilitation records
Description of unintended events	Adverse events log, REDCap

191 **Acceptability**

192 The acceptability of the PR intervention among adults living with COPD and healthcare staff
 193 involved in its delivery will be assessed. Participants' experience of the PR, including any
 194 perceived benefits, challenges and changes they would make to the programme, will be explored
 195 in qualitative interviews and focus groups after their discharge assessment or withdrawal. The
 196 experience of healthcare professionals regarding the PR intervention, such as their confidence in
 197 delivering the programme, the components of PR, structure of PR, the patient adherence to the

198 PR exercises and how their perceptions changed over the course of the trial, insights into barriers
 199 and facilitators to referral, uptake and completion of PR ((i) attending at least 10 out of 12
 200 designated PR sessions and (ii) attending the follow-up evaluation) will be explored in
 201 qualitative interviews at the end of the trial.

202 **Secondary outcomes**

203 The secondary outcomes of this study are provided in table 2. Comparison of secondary outcome
 204 measures of baseline and post intervention, will describe any changes in the health of the adults
 205 living with COPD following completion of PR

Table 2: Secondary outcome measures

Outcome measures	Baseline	Post-intervention
Socio-demographics	x	
Lung health (spirometry data, smoking status, number of COPD exacerbations in the last year)	x	
Comorbidities	x	
Treatments	x	
Nutritional status (Body Mass Index, mid upper arm circumference, skinfold thickness, self-report seven-day diet diary)	x	x
Disease burden (MRC dyspnea grade, CAT, CCQ)	x	x
Economic impact of disease (WPAI)	x	x
Quality of life (EQ-5D-5L)	x	x
Pittsburgh Sleep Quality Index (PSQI)	x	x
Psychological wellbeing (Hospital Anxiety and Depression scale)	x	x
Physical function (5x sit-to-stand test)	x	x
Exercise capacity (ISWT, ESWT)	x	x
International Physical Activity Questionnaire (IPAQ)	x	x
Accelerometer assessed physical activity (ActiGraph wGT3x-BT)	x	x

206 MRC - Medical Research Council, CAT- COPD Assessment Test, CCQ - Clinical COPD Questionnaire,
 207 WPAI – Work Productivity and Activity Impairment questionnaire, EQ-5D-5L - EuroQol Five
 208 Dimensions Five Levels, ISWT - Incremental Shuttle Walk Test, ESWT - Endurance Shuttle Walk Tests

209 **Sample size and recruitment target**

210 This study is a feasibility trial that aims to provide data for an accurate estimation of the required
 211 sample size for future trials. Therefore, a formal sample size calculation is not required. We aim
 212 to recruit and randomise 50 participants to the study (25 in each group).

213 **Patient allocation, concealment, and blinding**

214 Randomisation will occur through random permuted blocks to either the intervention group (PR+
215 usual care) or control group (usual care) in ratio 1:1 using Sealed envelope™.

216 The computer-generated patient allocation sequence will be monitored by an individual who is
217 independent of the research team and will inform the research team of group allocations via
218 telephone. Participants will be informed about their group allocation after providing informed
219 consent and completing baseline assessments.

220 It will not be possible to blind patients to their group allocation due to the nature of PR. Research
221 staff will be blinded to outcome measures. Participants will be advised not to reveal their group
222 during the follow-up assessment. Any episodes of un-blinding will be documented and reported.

223 **Data collection**

224 *Phase 1: Qualitative assessment for adaptation of PR*

225 **Focus groups with patient and family caregivers**

226 Focus groups with adults living with COPD and separate focus groups with their family
227 members/ caregivers will be conducted until data saturation. We anticipate conducting up to 5
228 focus groups with 6-8 participants in each. Data will be collected during patients' clinic visits.
229 Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes,
230 and will be conducted face-to-face by an interviewer and note-taker (observer). Focus groups
231 will be transcribed verbatim, with identifiable information removed. Envisaged outcomes of the
232 focus groups will include Sri Lankan specific adaptation of PR.

233 **Interviews with healthcare professionals involving the treatment of COPD**

234 Up to 15 in-depth interviews with healthcare professionals will be conducted until data
235 saturation. Structured interviews will be conducted with healthcare professionals as convenient
236 to them without interfering with their routine work. Interviews will be audio-recorded and will
237 be conducted face-to-face by an interviewer. Interviews will be transcribed verbatim, with

238 identifiable information removed. Envisaged outcomes of the in-depth interviews will be a
239 suitable design and content of PR acceptable respiratory health care deliverers in Sri Lanka.

240 *Phase 2: Single blind randomised control feasibility trial*

241 Data will be collected by trained researchers, following standard operating procedures during
242 participants' clinic visits. Baseline and post intervention assessments will be carried out by the
243 blinded Medical Officers consulting at the study setting.

244

245 *Phase 3: Qualitative evaluation of the PR intervention*

246 **Focus groups with patients**

247 Participants allocated to the intervention group will be invited to participate in focus group
248 discussions at the end of their PR programme. Focus groups will give an insight on views,
249 experiences, opinions and recommendations which will inform future PR programmes. We
250 anticipate conducting up to 5 focus groups until data saturation. Each focus group discussion will
251 be conducted with 6-8 participants in each.

252 Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes,
253 and will be conducted by a trained moderator and a note-taker). Focus groups will be transcribed
254 verbatim, with identifiable information removed. Consent will be obtained from participants
255 prior to their involvement in focus groups.

256 **Interviews with PR staff**

257 Health care personnel involved in delivering PR will be invited to participate in in-depth
258 interviews at the end of the study to discuss aspects of feasibility and acceptability, such as
259 insights into barriers and facilitators to attendance, logistical barriers of running a PR programme
260 and their perceptions, confidence of programme delivery and patients' experiences of the
261 intervention. Details regarding previous experience on PR and prior training regarding PR will
262 be assessed using brief questionnaire before commencing the in-depth interviews. We anticipate
263 conducting up to 15 interviews, each expected to last approximately 15-60 minutes. Interviews

264 will be audio-recorded and will be conducted face-to-face by a trained interviewer. Interviews
265 will be transcribed verbatim, with identifiable information removed.

266 Book of testimonies and evaluation form

267 Participants within PR will be asked to log their experience of PR as they progress through the
268 programme. This will be in the form of a PR log book accessible to participants before, during
269 and after sessions, as well as a dedicated evaluation form which will be provided as
270 supplementary material. Staff involved in PR will also receive the same evaluation form at the
271 end of the study.

273 Sample characteristics

274 Basic demographics including age, sex, religion, nationality, marital status, age of leaving full-
275 time education, education level, ethnicity, employment status, monthly income, lung health,
276 smoking status (packs per year), biomass fuel exposure, primary respiratory diagnosis, time since
277 diagnosis in years, secondary respiratory diagnoses, family history of lung disease, comorbidities
278 will be recorded at baseline.

279 Lung function

280 Spirometry (post bronchodilator Forced Expiratory Volume in the first second (FEV₁), post
281 bronchodilator Forced Vital Capacity (FVC), FEV₁/FVC ratio, carboxyhemoglobin test¹⁹,
282 hospitalisations within the last 12 months, number of COPD exacerbations within the last 12
283 months, treatments will be collected as the baseline data prior to the randomisation of
284 participants.

285 Nutritional status

286 Height (Holtain stadiometer), weight (calibrated weight scale) will be measured and body mass
287 index will be calculated. Mid upper arm circumference of the participants will be measured using
288 a measuring tape and skinfold thickness of seven sites (triceps, mid axillary, subscapular, chest,
289 abdominal, supra iliac and thigh measurements) of the body will be measured using a validated
290 caliper. Triplicated measurements will be taken by the same investigator and mean value will be

1
2
3 291 used for the calculation of body fat mass. Fat free mass will be calculated using Durnin and
4
5 292 Womersley formula.^{20, 21} Body composition analysis will be assessed using bioelectrical
6
7 293 impedance (SFB7 Impedi Med dual frequency instrument, Impedi Med Limited, Australia) and
8
9 294 software version 5.2.4.0.²² Seven-day diet diary method will be used to assess the dietary history
10
11 295 and calorie intake.

12 13 296 Disease burden

14
15 297 Breathlessness will be measured using MRC dyspnoea grade (5-items).²³ The health-related
16
17 298 quality of life related to mobility, self-care, usual activities, pain/discomfort and anxiety-
18
19 299 depression will be measured using EQ-5D-5L (25-items),²⁴ Clinical status of the airways,
20
21 300 functional limitations and psychosocial dysfunction will be determined using CCQ (10 -items),²⁵
22
23 301 CAT (8-items) will be used to determine the severity of the COPD,²⁶ Modified brief pain
24
25 302 inventory (3-items) will determine the commonly reported chest pain, WPAI (8-items) will be
26
27 303 used to measure the effect of severity of COPD and general health on work productivity and
28
29 304 regular activities²⁷ and HADS (14-items) will be used to measure the patient's emotional state
30
31 305 and the presence or absence of clinically significant anxiety and depression.²⁸ Sleep quality of
32
33 306 the participants will be measured using Pittsburgh Sleep Quality Index (PSQI)²⁹. Disease burden
34
35 307 will be measured as baseline data prior to the randomisation and post-intervention data.

36 308 Exercise capacity

37
38 309 Following a safety assessment for absolute and relative contraindications for field walking
39
40 310 tests³⁰, maximal exercise capacity will be assessed using the incremental shuttle walking test
41
42 311 (ISWT)³¹ and endurance shuttle walking test (ESWT).¹⁸ The ISWT and ESWT also include a
43
44 312 pre-test and post-test measure of SpO₂, blood pressure, Borg rating of breathlessness³², heart
45
46 313 rate, Borg rate of perceived exertion.³³ The sit-to stand test will be completed for five continuous
47
48 314 repetitions, to measure lower limb movement and strength.³⁴ All measures of exercise capacity
49
50 315 will be measured at baseline prior to the randomisation and post-intervention.

51 316 Physical activity

52
53 317 Subjective health-related physical activity will be measured with the International Physical
54
55 318 Activity Questionnaire (IPAQ)³⁵ at baseline prior to the randomisation and post-intervention.

319 Participants will be asked to wear an activity monitor (ActiGraph wGT3X-BT, ActiGraph,
 320 Pensacola, FL, USA), able to detect a range of PA intensities³⁶, on the right anterior hip during
 321 waking hours for seven days prior to attending PR (baseline) and for the seven consecutive days
 322 prior to their discharge assessment (follow-up); taking it off for water-based activities and sleep.
 323 The collection of physical activity data will coincide with a 7-day diet diary. Printed instructions
 324 will be provided to the participants regarding how to wear the monitor.

325 Full accelerometry methodology is provided in Table 3. Data will be processed as 60-s epoch
 326 files in ActiLife version 6.13.4 (ActiGraph, Pensacola, FL, USA). Non-wear will be defined as
 327 60-minutes of consecutive zero counts with allowance for 2-minutes of interruptions.³⁷

328 Adherence to wearing the monitors will be assessed by examining the proportion of participants
 329 providing valid accelerometer data across a range of valid days ($\geq 1-7$ days) and minimum wear
 330 time ($\geq 1-12$ hours) thresholds. For reported group averages, only participants providing ≥ 4 valid
 331 days of ≥ 8 hours, for both time points will be included in the analyses.³⁸ Step count, time spent
 332 in different absolute intensity classifications of physical behaviours³⁹ and average movement
 333 intensity (activity counts per minute) will be reported. Time spent in physical activity matching
 334 participants' prescribed walking exercise intensity will be derived by aligning the average
 335 walking speed during the ESWT with the activity monitor counts per minute.

336

Table 3: Accelerometry data collection and processing parameters

Accelerometer Model	ActiGraph wGT3X-BT (version 6.13.4; firmware 1.9.2)
Serial number range	Twenty unique devices will be used ranging from MOS2E09190601 to MOS2E24190146 averaging six deployments per device (same serial used for baseline and follow-up wear periods)
Piezosensor orientation	Triaxial
Mode setup	Mode 29 (x, y, z, steps, lux)
Original sample rate	100 Hz (.gt3x file format)
Deployment method	Baseline: Fitted by research team on Day 0 (Baseline PR Assessment) Fitted by participant on Day 1 Follow-up: Fitted by research team Day 0 (11 th /12 th session) Fitted by participant on Day 1
Location worn	Anterior hip adjacent to the mid-line of the thigh
Requested days of wear	7 days of free-living (Day 1-7; 10,080 epochs)

Initialization	Not deployed in delay mode in order to standardised capture of Day 0 (00:00) with stop time based on date of first PR class (baseline) and data of discharge assessment (follow-up)
Wear instructions	Wear continuously except for sleep and water based activities
Non-wear appropriation	≥ 60 min of consecutive 0s with allowance for 2 minutes of interruptions were deemed biologically implausible and coded as non-wear
Valid day criteria	≥ 8 hours of valid waking wear time
Valid file	≥ 4 valid days for each of the two time points
Missing data	Data modelling or imputation will not be performed
Epoch length	60 seconds
Intensity classification (absolute)	Uniaxial (x-axis) cut-points as follows: Sedentary time < 100 cpm; Light intensity 100-2019 cpm; Moderate intensity 2020-5998cpm; Vigorous intensity ≥ 5999 cpm (Moderate-to-vigorous intensity ≥ 2020 cpm)
Intensity classification (relative)	Uniaxial (x-axis) cut-points based on Endurance Shuttle Walk Test performance

337

338 Patient and Public Involvement

339 Adults living with COPD often tell us how having COPD impacts their lives and that they often
340 find it challenging to know what they can do to better manage their condition. When they talk
341 about their self-management strategies, it is clear that education and exercise support would be
342 of value. Also, they revealed the necessity of a programme to support their condition and
343 willingness to attend such a programme. Patients are generally positive about being able to
344 access support but there is little available to them. The study was planned to fulfill the need of
345 adults living with COPD. The delivery and adaptations of the trial intervention (Sri-Lankan
346 specific PR) will also be informed by the adults living with COPD, their care-givers /family
347 members and health care professionals. Priorities, experience, and preferences of the
348 stakeholders will be utilized to design the PR. Health care professionals involved in the treatment
349 of COPD at Central Chest Clinic will be involved in the recruitment as key informants and
350 conduct of the study. The feasibility and acceptability of the PR intervention among adults living
351 with COPD and healthcare staff involved in its delivery will be assessed in qualitative interviews
352 at the end of the trial. The results of the trial will be disseminated through patient and public
353 involvement events, local and international conference proceedings. As well as all the research

354 participants, stakeholders and individuals with COPD will be openly invited to take part in an
 355 event organized at the central chest clinic to reveal the study findings.

356

357 **Costing**

358 As part of this trial, the cost of creating a Sri-Lankan adapted PR programme will be calculated.
 359 This will include both single and recurrent costs. Single payments include the necessary costs to
 360 set up and run a programme, whilst recurrent cost refers to any item with a life expectancy of 1
 361 year or less and typically includes disposable materials.⁴⁰ The fixed costs will be captured prior
 362 to the first participant enrolling into the programme and the recurrent costs will be collected at
 363 the mid-stage of recruitment. An average cost per participant will be calculated. Table 4
 364 demonstrates the variables that will be used to calculate fixed and recurrent costs.

365

Table 4: The variables used to calculate fixed and recurrent costs (not an exhaustive list)

Fixed costs	Recurrent costs
Venue hire	Venue hire
Electrical equipment (laptop, printer, projector)	Staff time to conduct PR (assessment at baseline and discharge, conduct PR classes, telephone calls and data entry)
Equipment for PR (weights, treadmill, cycle ergometer, country-specific equipment, step-up box, chairs)	Disposable equipment (for blood glucose monitor, spirometer mouthpieces, nose-clips, glyceryl trinitrate spray)
Equipment for shuttle walking tests (cones, licences, stop watches, tape measure, electrical equipment to play audio)	Servicing costs (spirometer, PR equipment, specifically treadmills and cycle ergometers)
Equipment for PR assessment (height stadiometer, weight scales, sphygmomanometer, pulse oximeter, spirometer, calibration syringe, country-specific equipment)	Miscellaneous (Oxygen cylinders, questionnaire licences, stationery (paper))
Additional safety equipment (blood glucose monitor, Oxygen cylinder holder)	

Miscellaneous (filing cabinets, storage units, questionnaire translations, questionnaire licences, staff uniform)	
---	--

366

367

368 **Data management**

369 Data collected during the study will be entered into a database using Research Electronic Data
370 Capture (REDCap), which is a web-based platform.⁴¹ Access to the database will be via a secure
371 password protected web-interface. The participants will be identified by a study-specific
372 identification code. Data will be validated using real-time data entry validation and electronic
373 checks lead by the Independent Data Monitoring Committee (IDMC), established at the
374 University of Leicester, UK.

375 **Quantitative data analysis**

376 The data will be analyzed using IBM SPSS Statistics for Windows, Version 23.0. Data for
377 baseline and follow-up time-points will be presented as descriptive statistics as appropriate. No
378 inferential statistics will be performed due to the feasibility design of the trial.

379 **Qualitative data analysis**

380 Qualitative data will be analyzed using Thematic Analysis. This approach follows six distinct
381 stages: familiarization with data; generating initial codes; searching for themes; reviewing
382 themes; defining and naming themes and producing the report.⁴² The responsible investigator
383 will carry out initial coding and a sample of focus group transcripts will be coded by a second
384 member of the team to improve consistency and to enhance interpretive authenticity. Throughout
385 the data analysis, the team will meet to discuss and review emerging themes and search the
386 accounts that provide contesting views of the same phenomena. Close attention will be paid to
387 the complexity and interactions inherent in the focus group data.⁴³

388 **Adverse events**

1
2
3 389 All adverse events and serious adverse events will be recorded on an adverse event log, within
4
5 390 study trial management paperwork, case report forms and REDCap. There will be no formal
6
7 391 interim analysis of data due to the feasibility nature of the trial. The IDMC will review high level
8
9 392 safety data. Adverse events will be monitored at least every month, and as needed on an ad hoc
10
11 393 basis, to ensure the continuing safety of the participants. The Scientific Committee will
12
13 394 determine the need to terminate the trial. Participants who experience any such event will be
14
15 395 directed to the appropriate hospital and all the necessary care will be ensured and followed-up
16
17 396 until the participant has resolved or stabilized.

18 397

21 398 **Ethics and dissemination**

23 399 Ethical approval was obtained from the ethics review committee of the Faculty of Medical
24
25 400 Sciences, University of Sri Jayewardenepura (FMS/USJP ERC 64/19) and the University of
26
27 401 Leicester, United Kingdom (26770). Further permission for the proposed study will be obtained
28
29 402 from the relevant authority at the Central Chest Clinic, Colombo, Sri Lanka. Privacy and the
30
31 403 confidentiality of all information and identities of participants will be strictly maintained and will
32
33 404 not be disclosed when publishing the results of the study. A copy of the test results obtained will
34
35 405 be provided to each participant at the end of the trial for subsequent follow-up and treatment at
36
37 406 the clinic. Compensation for travelling will be provided to all the participants. All study
38
39 407 documents will be translated to Sinhala and Tamil to ensure clear communication. Participation
40
41 408 will be without compulsion and each participant has the right to withdraw at any time, without
42
43 409 providing a reason. Consent form and data sheets will be securely stored in a separate locked
44
45 410 cupboard. Study computers will be password protected. The participants (adults living with
46
47 411 COPD) of the phase 1 study also will be provided the opportunity to participate the PR. All the
48
49 412 data will be stored safely up to 6 years and after 6 years consent form and data sheets will be
50
51 413 disposed of appropriately. Study team and IDMC only will have access to final trial dataset. Data
52
53 414 from the Global RECHARGE Core Dataset will be made available following the completion of
54
55 415 this project and we are considering the best tools to use to make this database available to the
56
57 416 wider community. Any modifications of the protocol will be updated on trial registry (ISRCTN)
58
59 417 and will be informed to the ethics review committee and the participants. Participants will be

1
2
3 418 provided the provisions for re-consenting after any change of the approved protocol. It will be
4
5 419 made clear in the publication of trial findings.
6
7

8 420

9
10 421

11 12 13 422 **Author affiliations**

14
15 423 ¹Faculty of Health Sciences, KAATSU International University, Sri Lanka

16 424 ²Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-
17
18
19 425 Respiratory, University Hospitals of Leicester NHS Trust, UK

20 426 ³Department of Respiratory Sciences, University of Leicester, Leicester, UK,

21 427 ⁴Sports Medicine Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka

22 428 ⁵Department of Nursing and Midwifery, Faculty of Allied Health Sciences, University of Sri
23
24
25 429 Jayewardenepura, Sri Lanka

26 430 ⁶National Hospital of Sri Lanka and Central Chest Clinic, Colombo, Sri Lanka

27 431 ⁷Primary Care Respiratory Group, Sri Lanka

28 432 ⁸Faculty of Health, University of Plymouth, UK

29 433 ⁹School of Sport, Exercise and Health Sciences, Loughborough University, UK

30 434 ¹⁰Department of Economics, University of Sheffield, Sheffield, UK

31 435 ¹¹Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka
32
33
34
35
36
37
38
39 436

40 41 42 437 **Author contribution**

43
44 438 All authors (Akila R Jayamaha, Chamilya H Perera, Mark W Orme, Amy V Jones, Upendra K D
45
46 439 C Wijayasiri, Thamara D Amarasekara, Ravini de S Karunatillake, Amitha C Fernando,
47
48 440 Seneviratne A L P De S., Andy Barton, Rupert Jones, Zainab K Yusuf, Ruhme B Miah, Dominic
49
50 441 Malcolm, Jesse A Matheson, Robert C Free, Adrian Manise, Michael C Steiner, Savithri W
51
52 442 Wimalasekera, Sally J Singh) have substantially contributed to the conception and design of the
53
54 443 study. Akila R Jayamaha drafted the manuscript. All authors of the paper have revised the
55
56
57
58
59
60

1
2
3 444 content and approved the final version to be published. All authors are accountable for all aspects
4
5 445 of the work.

6
7
8 446 **Funding** This research was funded by the National Institute for Health Research (NIHR)
9
10 447 (17/63/20) using UK aid from the UK Government to support global health research. The views
11
12 448 expressed in this publication are those of the author(s) and not necessarily those of the NIHR or
13
14 449 the UK Department of Health and Social Care.

15
16 450 **Competing interests** None declared.

17
18 451

19
20 452 [insert figure caption]

21
22
23 453 Figure 1: Flow of participant of the three phases of the study

24
25
26 454


27
28 455 References

- 29
30
31 456 1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for
32
33 457 the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the
34
35 458 GOLD science committee report 2019. *Eur Respir J*. 2019;53(5).
- 36 459 2. Alwan A. Global Status Report on Non-Communicable Diseases. WHO, 2010
- 37
38 460 3. World Health Organization. Global surveillance, prevention and control of Chronic
39
40 461 Respiratory Diseases, Switzerland, 2007; 22-23.
- 41 462 4. Amarasiri L, Fernando A, Gunasekara K, Gunasinghe W, Madegedara D, Wickramasinghe
42
43 463 R. The prevalence of Chronic Obstructive Pulmonary Disease in Sri Lanka. *European*
44
45 464 *Respiratory Journal*, 2017; 2017(50):1212.
- 46 465 5. World Health Organization. WHO strategy for prevention and control of chronic respiratory
47
48 466 diseases, Geneva, 2017.
- 49
50 467 6. Yasaratne D, Dharmage SC. Letter from Sri Lanka. *Respirology*. 2020;25:339-41.
- 51
52 468 7. Pinnock H, Kendall M, Murray SA, Worth A, Levack P, Porter M, et al. Living and dying
53
54 469 with severe chronic obstructive pulmonary disease: Multi-perspective longitudinal qualitative
55
56 470 study. *BMJ*. 2011;342:268.

- 1
2
3 471 8. Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K. Comment Exercise and pulmonary
4 472 rehabilitation for people with chronic lung disease in LMICs : challenges and opportunities.
5 473 *Lancet Respir* [Internet]. 2019;7(12):1002–4.
6
7 474 9. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American
8 475 Thoracic Society Documents American Thoracic Society / European Respiratory Society
9 476 Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med*. 2006;173(May):1390-
10 477 413.
11
12 478 10. Mccarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y, et al. Pulmonary
13 479 rehabilitation for chronic obstructive pulmonary disease (Review). *Cochrane Database Syst*
14 480 *Rev*. 2015;2015(2).
15
16 481 11. Jones AW, Taylor A, Gowler H, Kelly NO, Ghosh S, Bridle C. Systematic review of
17 482 interventions to improve patient uptake and completion of pulmonary rehabilitation in
18 483 COPD. *ERJ Open Res*. 2017;3.
19
20 484 12. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit
21 485 2013 statement: Defining standard protocol items for clinical trials. *Chinese J Evidence-Based*
22 486 *Med*. 2013;13(12):1501–7.
23
24 487 13. Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on
25 488 pulmonary rehabilitation in adults: accredited by NICE. *Thorax*. 2013;68:ii1-ii30.
26
27 489 14. Ries AL, Bauldoff GS, Casaburi R, Mahler DA, Rochester CL, Herrerias C. Pulmonary
28 490 Rehabilitation; Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest*.
29 491 2007;131(5):4S-42S.
30
31 492 15. Blackstock FC, Evans RA. Rehabilitation in lung diseases: ‘Education’ component of
32 493 pulmonary rehabilitation. *Respirology*. 2019;24(9):863–70
33
34 494 16. Spencer LM, McKeough ZJ. Maintaining the benefits following pulmonary rehabilitation:
35 495 Achievable or not? *Respirology*. 2019;24(9):909–15.
36
37 496 17. Armstrong M, Vogiatzis I. Personalized exercise training in chronic lung diseases.
38 497 *Respirology*. 2019;24(9):854–62.
39
40 498 18. Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk :
41 499 a new field test for the assessment of endurance capacity in chronic obstructive pulmonary
42 500 disease. *Thorax*. 1999;54(2):213–22
43
44 501 19. Yasuda H, Yamaya M, Nakayama K, Ebihara S, Sasaki T, Okinaga S, et al. Increased
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 502 Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease. *Am*
4 503 *J Respir Crit Care Med.* 2005;171:1246–51.
- 5
6 504 20. Durkin JVGA, Womersley J. Body fat assessed from total body density and its estimation
7 505 from skinfold thickness: measurements on 481 men and women aged from 16 to 72 Years. *Br*
8 506 *J Nutr.* 1974;32:77–96.
- 9
10 507 21. Doña E, Oliveira C, Palenque FJ, Porras N, Dorado A, Martín-valero R, et al. Body
11 508 Composition Measurement in Bronchiectasis: Comparison between Bioelectrical Impedance
12 509 Analysis, Skinfold Thickness Measurement, and Dual-Energy X-ray Absorptiometry before
13 510 and after Pulmonary Rehabilitation. *J Acad Nutr Diet.* 2018;118(8):1464–73.
- 14
15 511 22. Lanerolle MD, Lanerolle P, Atukorala S, Silva A De. Enhancing the accuracy of bio
16 512 impedance analysis in assessing total body water. *Int J Body Compos Res.* 2012;10(1):29–34.
- 17
18 513 23. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the
19 514 Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with
20 515 chronic obstructive pulmonary disease. *Thorax.* 1999;54:581–6.
- 21
22 516 24. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
23 517 preliminary testing of the new five-level version of EQ-5D (EQ-5D5L). *Quality of Life*
24 518 *Research.* 2011;20(10):1727-736.
- 25
26 519 25. Van der Molen T, Willemse BW, Schokker S, et al. Development, validity and
27 520 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes.* 2003;1:13.
- 28
29 521 26. Papaioannou M, Pitsiou G, Manika K, Kontou P, Zarogoulidis P, Sichletidis L, Kioumis IP.
30 522 COPD assessment test: A simple tool to evaluate disease severity and response to treatment.
31 523 *J of Chronic Obstructive Pulmonary Disease.* 2014;11:489- 95.
- 32
33 524 27. Reilly MC, Zbrozek IAS, Dukes EM. The Validity and Reproducibility of a Work
34 525 Productivity and Activity Impairment Instrument. *Pharmacoeconomics.* 1993;4(5):353–65.
- 35
36 526 28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica*
37 527 *Scandinavica.* 1983;67(6):361-70.
- 38
39 528 29. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new
40 529 instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28:193–213
- 41
42 530 30. Weisman IM, Marciniuk D, Martinez FJ, Sciruba F, Sue D, Myers J, et al. American
43 531 Thoracic Society / American College of Chest Physicians ATS / ACCP Statement on
44 532 Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003;167:211–77.
- 45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 533 31. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking
4 534 test of disability in patients with chronic airways obstruction. *Thorax*. 1992;47(12):1019-24.
5
6 535 32. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with
7 536 respiratory disease. *Med Sci Sports Exerc*. 1994;26:1078-1081.
8
9 537 33. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14:377-
10 538 381
11
12 539 34. Jones SE, Kon SSC, Canavan JL, Patel MS, Clark AL, Nolan CM, et al. The five-repetition
13 540 sit-to-stand test as a functional outcome measure in COPD. *Thorax*. 2013;68:1015-20.
14
15 541 35. Booth M: Assessment of physical activity: An International perspective. *Research Quarterly*
16 542 *for Exercise and Sport*. 2000, 71 (2): 114-120.
17
18 543 36. Bassett DR, John D. Use of pedometers and accelerometers in clinical populations: validity
19 544 and reliability issues. *Phys Ther Rev*. 2010;15:135-42.
20
21 545 37. Choi L, Liu Z, Matthews CE, Buchowski MS. Validation of accelerometer wear and nonwear
22 546 time classification algorithm. *Med Sci Sports Exerc*. 2011;43:357-64.
23
24 547 38. Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, et al.
25 548 Standardizing the analysis of physical activity in patients with COPD following a pulmonary
26 549 rehabilitation program. *Chest* 2014 Aug;146(2):318-327
27
28 550 39. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in
29 551 the United States measured by accelerometer. *Med Sci Sports Exerc* 2008 Jan;40(1):181-188.
30
31 552 40. Lucas AO, Gilles HM. Approaches to economic evaluation. *Short Textbook of Public Health*
32 553 *Medicine for the Tropics*. 2002. CRC Press.
33
34 554 41. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap
35 555 consortium: Building an international community of software platform partners. *J Biomed*
36 556 *Inform*. 2019;95.
37
38 557 42. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3:77-101
39
40 558 43. Maguire M, Delahunt B. Doing a Thematic Analysis : A Practical, Step-by-Step Guide for
41 559 Learning and Teaching Scholars. *AISHE-J*. 2017;8(3):3351-14.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Appendices

Information sheet

Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

I am Prof. S. W. Wimalasekera, of Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura. I and my team of health care personnel are, conducting a research on “Testing the Feasibility and Acceptability of a Culturally Appropriate Hospital-Based Pulmonary Rehabilitation (PR) Programme for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka”. I invite you to participate in the study. Please take time and read the following information carefully before giving your consent. You are free to ask questions to clarify facts which are not clear or ask for more information if you need.

Purpose of the study

The purpose of this study is to devise an appropriate PR programme and then determine the feasibility and acceptability of this programme for adults living with COPD in Sri Lanka and assess the potential for a future trial of its effectiveness.

When you participate you will be required to do the following

You will be requested to participate several components of the study.

You will participate in a group discussion conducted in a quiet room in the clinic (conference hall) with very minimal disturbances. At the beginning of the discussion you will answer some questions regards your personal information, (age, gender, history of the disease condition). Then the interviewer will ask some questions regarding your thoughts and ideas about pulmonary rehabilitation. You and your group members can freely comment on the questions or can add your ideas to the discussion. The interview takes around forty-five minutes of time.

You will also participate in a feasibility trial which you will be allocated to one of the two groups. One group will receive usual care and PR and the other group will receive only usual care which consists of pharmacological treatment and brief information about disease condition, medication and inhaler techniques. PR is typically a 6-week rolling programme and consisting of 12 sessions in total, delivered twice a week. Sessions usually last approximately two hours, with one hour for exercise training and one hour for education. Some routine and specific test and measurements will be taken before and after the intervention will describe any changes in the health of the adults living with COPD.

If you are allocated to the group who receive the PR, you will be asked to share your experiences regarding the PR and subjected modification and opinions on pulmonary rehabilitation.

In order to maintain accuracy, and to keep records, your discussion will be recorded by the research team members with your permission. Your participation in the project will remain confidential and the provision of your name and address is necessary for us to maintain records. Any personal information gathered during the study will not be disclosed to a third party. Your responses to the questions and will

1
2
3 only be used for the purpose of this project. You can be assured that you will remain anonymous if you
4 take part in the project. Your participation in this project is entirely voluntary. You are not obliged to take
5 part. If you do not wish to take part, you can withdraw without giving a reason and your medical care will
6 not be affected, further you will not be contacted again. Similarly, if you do agree to participate, you are
7 free to withdraw at any time during the project.
8
9
10

11 **What are the possible benefits of taking part?**

12
13 By participating in the study, you will contribute to develop a PR programme which helps to improve the
14 quality of life of the adults living with COPD. As well as you will contribute to determine the feasibility
15 and acceptability of this programme within the health care system in Sri Lanka.
16
17
18

19 **What are the possible disadvantages and risks of taking part?**

20
21 You will be undertaking some physical tests as part of the research. Therefore, there may be a very small
22 risk of falls, breathlessness, changes in blood pressure and changes in heart rate. However, these risks are
23 very rare, and trained staff and emergency equipment will be available to deal with any serious events.
24 Participants who experience any such event will be directed to the appropriate hospital and all the
25 necessary care will be ensured and followed-up until the participant has resolved or stabilized.
26
27
28

29 **What will happen if you don't carry on with the study?**

30
31 If you withdraw from the study all the information and data collected from you, to date, will be destroyed
32 and your name would be removed from all the research study files. There will not be any loss or impact
33 on your routine medical care which you are entitled to.
34
35
36

37 **What will happen to the results of the research study?**

38
39 The results of all the participants of the study will be used for scientific research. All data will be
40 available only to the researchers and information provided will be strictly confidential. Your participation
41 in the study is highly appreciated. Privacy and confidentiality of data gathered is completely secure and
42 will be used only for research purposes. If you have any questions or any concerns with regards to the
43 study and need further information you can call the telephone number listed below. Further you can send
44 any complaint to the above postal address or email address.
45
46
47

48 Yours faithfully

49 Prof. S.W. Wimalasekera

50 Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura

51 T.P No. 0777487203 e-mail : savithriww@yahoo.com

52 Ethics Review Committee – University of Sri Jayewardenepura - +94 11 2758000 Ext 4075e
53
54
55
56
57
58
59
60

Consent Form: Randomised Controlled Feasibility Trial

Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

- 1. Have you read the information sheet? (please keep a copy for yourself) YES/NO
- 2. Have you had an opportunity to discuss this and ask any questions? YES/NO
- 3. Have you had satisfactory answers to all your questions? YES/NO
- 4. Have you received enough information about the study? YES/NO
- 5. Who explained the study to you-----
- 6. Do you understand that you are free to withdraw from the study at any time,
without having to give a reason YES/NO
- 7. All personal details will be treated as STRICTLY CONFIDENTIAL.
Do you give your permission for these individuals to have access to the records? YES/NO
- 8. Have you had sufficient time to come to your decision? YES/NO
- 9. Do you agree to take part in this study? YES/NO

Participant’s signature ----- Date-----

By the Witness

I have been present while the procedure was explained to the participant and I have witness his/ her willingness to take part in the study.

Signature of witness----- Date-----

(The witness should be a person not connected to the study)

Name -----

Contact details-----

BMJ Open

Protocol for the Cultural Adaptation of Pulmonary Rehabilitation and Subsequent Testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041677.R2
Article Type:	Protocol
Date Submitted by the Author:	05-Nov-2020
Complete List of Authors:	<p>Jayamaha, Akila; KIU, Health Sciences Perera, Chamilya; KIU, Health Sciences Orme, Mark; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Jones , Amy; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory; University of Leicester, Department of Respiratory Sciences Wijayasiri, Upendra; Colombo South Teaching Hospital, Sports Medicine Unit Amarasekara, Thamara; University of Sri Jayewardenepura, Faculty of Allied Health Sciences Karunatilake, Ravini ; National Hospital of Sri Lanka, Central Chest Clinic Fernando, Amitha; National Hospital of Sri Lanka, Central Chest Clinic Seneviratne, Anthony ; Primary Care Respiratory Group Barton, Andy; University of Plymouth, Faculty of Health Jones, Rupert; University of Plymouth, Faculty of Health Yusuf, Zainab; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University Hospitals of Leicester NHS Trust; University of Leicester, Department of Respiratory Sciences Miah, Ruhme ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory Malcolm, Dominic; Loughborough University, School of Sport, Exercise and Health Sciences Matheson, Jesse; University of Sheffield, Department of Economics Free, Robert; University of Leicester, Department of Respiratory Sciences, Manise, Adrian ; University of Leicester, Department of Respiratory Sciences Steiner, michael ; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory</p>

	Wimalasekera, Savithri; University of Sri Jayewardenepura, Faculty of Medical Sciences Singh, Sally; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory
Primary Subject Heading :	Respiratory medicine
Secondary Subject Heading :	Rehabilitation medicine
Keywords :	REHABILITATION MEDICINE, Chronic airways disease < THORACIC MEDICINE, Emphysema < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Protocol for the Cultural Adaptation of Pulmonary Rehabilitation and Subsequent Testing**
5
6 2 **in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive**
7
8 3 **Pulmonary Disease in Sri Lanka**
9

10 4 Akila R Jayamaha ¹, Chamilya H Perera ¹, Mark W Orme ^{2,3}, Amy V Jones ^{2,3}, Upendra K D C Wijayasiri
11 5 ⁴, Thamara D Amarasekara ⁵, Ravini de S Karunatillake ⁶, Amitha C Fernando ⁶, Seneviratne A L P De
12 6 S.⁷, Andy Barton ⁸, Rupert Jones ⁸, Zainab K Yusuf ^{2,3}, Ruhme B Miah ^{2,3}, Dominic Malcolm ⁹, Jesse A
13 7 Matheson ¹⁰, Robert C Free ³, Adrian Manise ³, Michael C Steiner ^{2,3} Savithri W Wimalasekera ¹¹, Sally J
14 8 Singh ^{2,3}
15 9

16 10 Correspondence to Akila Randika Jayamaha/1226arj@gmail.com/akila@kiu.ac.lk
17

18 11 **Abstract**
19

20
21 12 **Introduction** International guidelines recommend pulmonary rehabilitation (PR) should be
22
23 13 offered to adults living with COPD, but PR availability is limited in Sri Lanka. Culturally
24
25 14 appropriate PR needs to be designed and implemented in Sri Lanka. The study aims to adapt PR
26
27 15 to the Sri Lankan context and determine the feasibility of conducting a future trial of the adapted
28
29 16 PR in Sri Lanka.

30
31 17 **Methods and analysis** Eligible participants will be identified and will be invited to take part in
32
33 18 the randomised controlled feasibility trial, which will be conducted in Central Chest Clinic,
34
35 19 Colombo, Sri Lanka. A total of 50 participants will be recruited (anticipated from April 2021) to
36
37 20 the trial and randomised (1:1) into one of two groups; control group receiving usual care or the
38
39 21 intervention group receiving adapted PR. The trial intervention is a Sri Lankan specific PR
40
41 22 programme, which will consist of 12 sessions of exercise and health education, delivered over 6
42
43 23 weeks. Focus groups with adults living with COPD, caregivers and nurses and in-depth
44
45 24 interviews with doctors and physiotherapist will be conducted to inform the Sri Lankan specific
46
47 25 PR adaptations. After completion of PR, routine measures in both groups will be assessed by a
48
49 26 blinded assessor. The primary outcome measure is feasibility, including assessing eligibility,
50
51 27 uptake and completion. Qualitative evaluation of the trial using focus groups with participants
52
53 28 and in-depth interviews with PR deliverers will be conducted to further determine feasibility and
54
55 29 acceptability of PR, as well as the ability to run a larger future trial.

56 30 **Ethics and dissemination** Ethical approval was obtained from the ethics review committee of
57
58 31 Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and University of
59

1
2
3 32 Leicester, UK. The results of the trial will be disseminated through patient and public
4
5 33 involvement events, local and international conference proceedings, and peer-reviewed journals.
6

7
8 34 Trial registration: ISRCTN13367735
9

10 35 **Keywords:** COPD, Pulmonary Rehabilitation, Exercise, Education, Sri Lanka
11
12 36
13 37

14 38 **Strengths and limitations**

- 15 39
- 16 40 • This study is the first examining the feasibility and acceptability of a culturally
17 appropriate pulmonary rehabilitation programme for adults with COPD in Sri Lanka.
 - 18 41 • Taking a mixed-method approach, this study will provide a rich insight into delivering a
19 trial of pulmonary rehabilitation in the Sri Lankan context.
 - 20 42 • This study is a single center feasibility trial. As such, whilst findings will be an important
21 first step in understanding the potential role of pulmonary rehabilitation in Sri Lanka and
22 low- and middle-income countries more broadly, findings may not be generalizable to
23 other regions of the world.
24 44
25 45
26 46
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 INTRODUCTION

48 Chronic obstructive pulmonary disease (COPD) is a progressive disease characterised by airflow
49 obstruction and breathlessness. COPD is a major cause of morbidity and mortality throughout the
50 world, corresponding to 6% of all deaths worldwide.¹ Further, more than 90% of COPD deaths
51 occur in low and middle-income countries.² The most recent estimate of COPD prevalence in
52 South Asia was 6.3%³ with a prevalence in Sri Lanka of 10.5%,⁴ similar to the estimated global
53 COPD prevalence of 11.7%.⁵ COPD is a significant burden to both patients and healthcare
54 services.⁶

55 Chronic cough with sputum, breathlessness, physical inactivity and exercise intolerance resulting
56 from dyspnoea or fatigue are common consequences of COPD.¹ Symptoms of COPD
57 progressively worsen and people can become breathless, even at rest. Daily activities often
58 become difficult as the condition worsens, impacting their quality of life.⁷ The impact of COPD
59 to the individual and to society makes the need for interventions to reverse the associated
60 disability of paramount importance.

61 International guidelines recommend that pulmonary rehabilitation (PR) should be routinely
62 offered to patients with chronic respiratory disease who have persistent symptoms, limited
63 activity, and/or are unable to adjust to illness.^{8,9} It is a low cost, high impact intervention that
64 improves the quality of life, reduces suffering, reduces mortality and reduces economic loss,
65 relieves dyspnoea and fatigue, improves exercise capacity, improves psychological and
66 emotional function, and enhances an individual's self-management of their condition.¹ Having
67 realised the benefits of PR in COPD, Western countries have incorporated this as an important
68 structural component of healthcare delivery services.¹⁰ Implementation of PR based as practiced
69 in Western countries, in Sri Lanka requires adaptation to the local health service, population and
70 culture. Despite its effectiveness, there is a significant need to understand the feasibility of
71 conducting PR in low resource Sri Lankan health care setting and the acceptability of PR among
72 Sri Lankan adults living with COPD and healthcare staff involved in its delivery. Uptake and
73 completion of PR even in Western countries is an on-going challenge.¹¹ The need to maximize
74 appeal of PR to patients and referrers is a global issue and one that is likely to be specific to a
75 given location and population. There remains an unmet need for PR in Sri Lanka. To be

1
2
3 76 successful, PR must be not only evidence-based, but also designed and implemented in a manner
4
5 77 sensitive to the context in which it is being delivered, such as culture and geography. Therefore,
6
7 78 the aim of this study is to devise an appropriate PR programme and then determine the feasibility
8
9 79 and acceptability of this programme for adults living with COPD in Sri Lanka and assess the
10
11 80 potential for a future trial of its effectiveness.

12
13 81 The objectives of the study are to:

- 14
15 82 1. Explore the needs and perceptions of adults living with COPD, their care-givers /family
16
17 83 members and health care professionals to inform the adaptations required for a PR programme
18
19 84 suitable for the Sri Lankan context.
20
21
22 85 2. Determine the feasibility of conducting adapted hospital-based PR for people living with
23
24 86 COPD.
25
26
27 87 3. Assess the acceptability of the PR among Sri Lankan adults living with COPD and healthcare
28
29 88 staff involved in its delivery.
30
31
32 89 4. Describe any changes in health of the adults living with COPD following completion of PR.
33
34 90 5. Assess the feasibility of a future trial and estimate the required sample size.
35
36
37
38
39

92 **METHODS AND ANALYSIS**

93 **Study design and registration**

40
41 94 The proposed study will be conducted in three phases. Phase 1: A qualitative study will be
42
43 95 conducted to inform the adaptations required to make PR specific to the Sri Lankan context.
44
45 96 Phase 2 is a single blind randomised control feasibility trial. Adults living with COPD will be
46
47 97 randomised (1:1) into adapted PR or usual care. Phase 3: Qualitative evaluation of the trial to
48
49 98 determine the feasibility and acceptability of PR deliverers and participants. The trial will be
50
51 99 conducted, analysed and reported according to the Standard Protocol Items: Recommendations
52
53 100 for Interventional Trials (SPIRIT) statement ¹² and trial has been registered on the ISRCTN
54
55 101 website. Study was commenced upon ethical approval on 24/07/2020 for Phase 1 of the study.
56
57 102 The design of the study and flow of participant enrolment is presented in figure 1.

103 **Study setting**

104 The study will be carried out at the Central Chest Clinic, Colombo, Sri Lanka which is a leading
105 health care facility that provides treatment for adults with respiratory disease. A room allowing
106 confidential discussions will be used for conducting focus group discussions among adults living
107 with COPD, their caregivers /family members, and nurses. Semi structured interviews will be
108 conducted among doctors and physiotherapists in a given quiet room at the Central Chest Clinic
109 as convenient to them and without interfering with their routine work. The venue for PR will be a
110 large room at the Central Chest Clinic.

111 **Participants**

112 Key informants and suitable participants for phase 1 of the study will be identified by the
113 researchers with the help of health care professionals involved in the treatment of COPD at
114 Central Chest Clinic. Suitable participants will be purposively selected and informed verbally
115 about the study by the researchers. After receiving a study information sheet, potential
116 participants will be contacted to arrange an appointment, if they wish to take part. An
117 opportunity to ask questions will be provided. If willing to take part in the study, they will be
118 asked to provide written informed consent. Multi-religious and multi-ethnic Sri Lankan cultural
119 diversity and gender will be considered when recruiting to the study. Adults living with COPD
120 aged ≥ 18 years and Medical Research Council (MRC) dyspnoea score grade 2 or higher, Family
121 member aged ≥ 18 years and looks after a patient with COPD and Health care professionals who
122 have more than 1-year experience of managing patients with COPD and working in the
123 government health care system of the country will be eligible to participate in the phase 1 of the
124 study. Participants who provide written informed consent will be enrolled in the study.

125 After the adaptation of PR in phase 1, suitable participants for the Phase 2 randomised controlled
126 feasibility trial will be identified by the Medical Officers in the Chest Clinic and will be invited
127 to take part in an eligibility assessment. This assessment will determine eligibility for entry into
128 the study. People eligible for inclusion in the trial will be: aged ≥ 18 years, will have a clinically
129 confirmed diagnosis of COPD by a physician, confirmed COPD with spirometry based on
130 GOLD criteria with $FEV_1/FVC < 0.7$, and $FEV_1 < 80\%$ predicted, ≥ 1 exacerbation required a
131 hospitalisation in the year preceding study, mMRC grade ≥ 2 and willing to provide informed
132 consent. Adults with comorbidities such as severe or unstable cardiovascular, other internal

1
2
3 133 diseases and locomotor difficulties that preclude the exercise or malignant disease or other
4
5 134 serious illness which will interfere with participation in the PR, will be excluded from the study.
6
7 135 Individuals not eligible for the study will be recorded on a study screening log.

8
9 136 [insert figure 1 here]

10
11 137

12 13 14 138 **Procedure**

15
16
17 139 Eligible participants will be informed verbally about the study by the Medical Officers of the
18
19 140 Central Chest Clinic. After receiving a study information sheet, potential participants will be
20
21 141 contacted to arrange an appointment, if they wish to take part. An opportunity to ask questions
22
23 142 will be provided. If willing to take part in the study, they will be asked to provide written
24
25 143 informed consent. Information regarding the interest of participation in the study will be taken as
26
27 144 field notes. Baseline outcome measures will be assessed. After baseline data collection,
28
29 145 participants will be randomised (1:1) into two groups. One group will receive usual care and PR
30
31 146 and the other group will receive only usual care which consists of pharmacological treatment and
32
33 147 brief information about disease condition, medication and inhaler techniques. Experiences of the
34
35 148 participants and PR deliverers regarding the acceptability and feasibility of PR will be explored
36
37 149 in interviews and focus groups during Phase 3 of the study. Participants who did not complete
38
39 150 the PR will be asked to take part in a drop-out interview and information provided freely by the
40
41 151 participants will be collected as field notes.

42
43 152

44 153 **Trial interventions**

45 154 **Intervention: Adapted pulmonary rehabilitation**

46
47 155 Sri-Lankan specific PR will comprise the core elements of an evidence based rehabilitation, a
48
49 156 programme of exercises ^{13, 14} and health education. ^{13, 14, 15} The detail of delivery and adaptations
50
51 157 of PR will be informed by findings of the Phase 1 of the study. PR is typically a 6-week rolling
52
53 158 programme that consists of 12 sessions in total. ^{13, 14} Sessions usually last approximately two
54
55 159 hours, with one hour for exercise training and one hour for education. All the education sessions
56
57 160 and the instructions during PR will be provided in Sinhala language as convenient to the
58
59 161 participants. The duration of the PR trial and frequency and duration of sessions will be

1
2
3 162 discussed during Phase 1. All staff delivering PR will be trained and assisted by a nursing
4 163 officer, a clinical nutritionist, an exercise physician and a physiotherapist. The venue for PR will
5 164 be at the Central Chest Clinic, Colombo, Sri Lanka. The Central Chest Clinic will have a
6 165 maximum capacity of 10 patients per PR class. The equipment required will be simple and
7 166 include chairs, weights, and simple exercise equipment based on local availability, suitability and
8 167 informed by qualitative work.¹⁶
9
10
11
12
13
14

15 169 In keeping with evidence-based guidelines^{13, 14}, discussions in Phase 1 will include the core
16 170 exercise component of PR, notably resistance training (e.g. upper and lower limbs) and aerobic
17 171 training (walking, sit-to-stand, step-ups) using minimal equipment and education. Each
18 172 participant's exercise regimen will be individually prescribed and progressed¹⁷ with walking
19 173 speed will be prescribed using the ISWT.¹⁸ The process in which this is achieved by patients will
20 174 be informed by Phase 1. The education component will be delivered by an interdisciplinary team
21 175 and will be informed by qualitative findings from Phase 1 with discussions facilitated by usual
22 176 education topics as described in guidelines.^{13, 14}
23
24
25
26
27
28
29

30 177 **Usual care**

31
32 178 Usual care will consist of pharmacological treatment and optimization, prescribed to patients
33 179 after consultation with Medical Officers at the Central Chest Clinic. Brief information about
34 180 disease condition, medication and inhaler techniques will be provided by Medical Officers and
35 181 Nurses. Pulmonary rehabilitation or any form of exercise recommendation is not part of usual
36 182 care.
37
38
39
40
41

42 183 **Outcomes**

43 44 45 184 **Primary outcome**

46
47 185 The primary outcome of the trial will be the feasibility and the acceptability of the PR
48 186 intervention.
49
50
51

52 187 **Feasibility**

53
54
55
56
57
58
59
60

188 Measures to assess feasibility are provided in table 1 and include the comprehensive assessment
 189 of the feasibility of patient recruitment and the intervention delivery.

Table 1: Primary outcome measures- Feasibility and operational experience assessment

Feasibility of patient recruitment	Data sources
Feasibility of screening and recruiting participants	Interviews with the healthcare professionals, screening log
Suitability of the inclusion criteria	Interviews with the healthcare professionals, screening log
Number of eligible patients, number of patients screened, number of patients invited to take part, actual number of participants who consent to take part	Screening log
Number of patients who refuse, drop out and the reasons for refuse and drop out	Interviews with the patients, screening log
Operational experience of intervention delivery	
Service provider and multi-disciplinary teams' willingness and ability to deliver the PR	Interviews with healthcare professionals
The practicality of delivering the intervention in the proposed setting	Interviews with healthcare professionals and focus groups with participants
The time needed to collect the data Baseline visit- Time taken for each measure (each individual questionnaire and physical measure) Follow-up visit- Time taken for each measure (each individual questionnaire and physical measure)	Interviews with the healthcare professionals, Rehabilitation records
Data completeness and accuracy	Interviews with the healthcare professionals, Rehabilitation records, RedCap
Adherence to home exercise	Interviews with the patients and self-report exercise diary
The training and resources needed to deliver the intervention (ensuring readiness for a future much larger multi-center trial)	Interviews with the healthcare professionals and focus groups with participants, Rehabilitation records
Description of unintended events	Adverse events log, REDCap

190 Acceptability

191 The acceptability of the PR intervention among adults living with COPD and healthcare staff
 192 involved in its delivery will be assessed. Participants' experience of the PR, including any
 193 perceived benefits, challenges and changes they would make to the programme, will be explored
 194 in qualitative interviews and focus groups after their discharge assessment or withdrawal. The
 195 experience of healthcare professionals regarding the PR intervention, such as their confidence in
 196 delivering the programme, the components of PR, structure of PR, the patient adherence to the

197 PR exercises and how their perceptions changed over the course of the trial, insights into barriers
 198 and facilitators to referral, uptake and completion of PR ((i) attending at least 10 out of 12
 199 designated PR sessions and (ii) attending the follow-up evaluation) will be explored in
 200 qualitative interviews at the end of the trial.

201 **Secondary outcomes**

202 The secondary outcomes of this study are provided in table 2. Comparison of secondary outcome
 203 measures of baseline and post intervention, will describe any changes in the health of the adults
 204 living with COPD following completion of PR

Table 2: Secondary outcome measures

Outcome measures	Baseline	Post-intervention
Socio-demographics	x	
Lung health (spirometry data, smoking status, number of COPD exacerbations in the last year)	x	
Comorbidities	x	
Treatments	x	
Nutritional status (Body Mass Index, mid upper arm circumference, skinfold thickness, self-report seven-day diet diary)	x	x
Disease burden (MRC dyspnea grade, CAT, CCQ)	x	x
Economic impact of disease (WPAI)	x	x
Quality of life (EQ-5D-5L)	x	x
Pittsburgh Sleep Quality Index (PSQI)	x	x
Psychological wellbeing (Hospital Anxiety and Depression scale)	x	x
Physical function (5x sit-to-stand test)	x	x
Exercise capacity (ISWT, ESWT)	x	x
International Physical Activity Questionnaire (IPAQ)	x	x
Accelerometer assessed physical activity (ActiGraph wGT3x-BT)	x	x

205 MRC - Medical Research Council, CAT- COPD Assessment Test, CCQ - Clinical COPD Questionnaire,
 206 WPAI – Work Productivity and Activity Impairment questionnaire, EQ-5D-5L - EuroQol Five
 207 Dimensions Five Levels, ISWT - Incremental Shuttle Walk Test, ESWT - Endurance Shuttle Walk Tests

208 **Sample size and recruitment target**

209 This study is a feasibility trial that aims to provide data for an accurate estimation of the required
 210 sample size for future trials. Therefore, a formal sample size calculation is not required. We aim
 211 to recruit and randomise 50 participants to the study (25 in each group).

212 **Patient allocation, concealment, and blinding**

213 Randomisation will occur through random permuted blocks to either the intervention group (PR+
214 usual care) or control group (usual care) in ratio 1:1 using Sealed envelope™.

215 The computer-generated patient allocation sequence will be monitored by an individual who is
216 independent of the research team and will inform the research team of group allocations via
217 telephone. Participants will be informed about their group allocation after providing informed
218 consent and completing baseline assessments.

219 It will not be possible to blind patients to their group allocation due to the nature of PR. Research
220 staff will be blinded to outcome measures. Participants will be advised not to reveal their group
221 during the follow-up assessment. Any episodes of un-blinding will be documented and reported.

222 **Data collection**

223 *Phase 1: Qualitative assessment for adaptation of PR*

224 **Focus groups with patient and family caregivers**

225 Focus groups with adults living with COPD and separate focus groups with their family
226 members/ caregivers will be conducted until data saturation. We anticipate conducting up to 5
227 focus groups with 6-8 participants in each. Data will be collected during patients' clinic visits.
228 Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes,
229 and will be conducted face-to-face by an interviewer and note-taker (observer). Focus groups
230 will be transcribed verbatim, with identifiable information removed. Envisaged outcomes of the
231 focus groups will include Sri Lankan specific adaptation of PR.

232 **Interviews with healthcare professionals involving the treatment of COPD**

233 Up to 15 in-depth interviews with healthcare professionals will be conducted until data
234 saturation. Structured interviews will be conducted with healthcare professionals as convenient
235 to them without interfering with their routine work. Interviews will be audio-recorded and will
236 be conducted face-to-face by an interviewer. Interviews will be transcribed verbatim, with

237 identifiable information removed. Envisaged outcomes of the in-depth interviews will be a
238 suitable design and content of PR acceptable respiratory health care deliverers in Sri Lanka.

239 *Phase 2: Single blind randomised control feasibility trial*

240 Data will be collected by trained researchers, following standard operating procedures during
241 participants' clinic visits. Baseline and post intervention assessments will be carried out by the
242 blinded Medical Officers consulting at the study setting.

243

244 *Phase 3: Qualitative evaluation of the PR intervention*

245 **Focus groups with patients**

246 Participants allocated to the intervention group will be invited to participate in focus group
247 discussions at the end of their PR programme. Focus groups will give an insight on views,
248 experiences, opinions and recommendations which will inform future PR programmes. We
249 anticipate conducting up to 5 focus groups until data saturation. Each focus group discussion will
250 be conducted with 6-8 participants in each.

251 Focus group discussions will be audio-recorded, expected to last approximately 45-90 minutes,
252 and will be conducted by a trained moderator and a note-taker). Focus groups will be transcribed
253 verbatim, with identifiable information removed. Consent will be obtained from participants
254 prior to their involvement in focus groups.

255 **Interviews with PR staff**

256 Health care personnel involved in delivering PR will be invited to participate in in-depth
257 interviews at the end of the study to discuss aspects of feasibility and acceptability, such as
258 insights into barriers and facilitators to attendance, logistical barriers of running a PR programme
259 and their perceptions, confidence of programme delivery and patients' experiences of the
260 intervention. Details regarding previous experience on PR and prior training regarding PR will
261 be assessed using brief questionnaire before commencing the in-depth interviews. We anticipate
262 conducting up to 15 interviews, each expected to last approximately 15-60 minutes. Interviews

263 will be audio-recorded and will be conducted face-to-face by a trained interviewer. Interviews
264 will be transcribed verbatim, with identifiable information removed.

265 Book of testimonies and evaluation form

266 Participants within PR will be asked to log their experience of PR as they progress through the
267 programme. This will be in the form of a PR log book accessible to participants before, during
268 and after sessions, as well as a dedicated evaluation form which will be provided as
269 supplementary material. Staff involved in PR will also receive the same evaluation form at the
270 end of the study.

271

272 Sample characteristics

273 Basic demographics including age, sex, religion, nationality, marital status, age of leaving full-
274 time education, education level, ethnicity, employment status, monthly income, lung health,
275 smoking status (packs per year), biomass fuel exposure, primary respiratory diagnosis, time since
276 diagnosis in years, secondary respiratory diagnoses, family history of lung disease, comorbidities
277 will be recorded at baseline.

278 Lung function

279 Spirometry (post bronchodilator Forced Expiratory Volume in the first second (FEV₁), post
280 bronchodilator Forced Vital Capacity (FVC), FEV₁/FVC ratio, carboxyhemoglobin test¹⁹,
281 hospitalisations within the last 12 months, number of COPD exacerbations within the last 12
282 months, treatments will be collected as the baseline data prior to the randomisation of
283 participants.

284 Nutritional status

285 Height (Holtain stadiometer), weight (calibrated weight scale) will be measured and body mass
286 index will be calculated. Mid upper arm circumference of the participants will be measured using
287 a measuring tape and skinfold thickness of seven sites (triceps, mid axillary, subscapular, chest,
288 abdominal, supra iliac and thigh measurements) of the body will be measured using a validated
289 caliper. Triplicated measurements will be taken by the same investigator and mean value will be

1
2
3 290 used for the calculation of body fat mass. Fat free mass will be calculated using Durnin and
4 291 Womersley formula.^{20, 21} Body composition analysis will be assessed using bioelectrical
5 292 impedance (SFB7 Impedi Med dual frequency instrument, Impedi Med Limited, Australia) and
6 293 software version 5.2.4.0.²² Seven-day diet diary method will be used to assess the dietary history
7 294 and calorie intake.

295 Disease burden

15 296 Breathlessness will be measured using MRC dyspnoea grade (5-items).²³ The health-related
16 297 quality of life related to mobility, self-care, usual activities, pain/discomfort and anxiety-
17 298 depression will be measured using EQ-5D-5L (25-items),²⁴ Clinical status of the airways,
18 299 functional limitations and psychosocial dysfunction will be determined using CCQ (10 -items),²⁵
19 300 CAT (8-items) will be used to determine the severity of the COPD,²⁶ Modified brief pain
20 301 inventory (3-items) will determine the commonly reported chest pain, WPAI (8-items) will be
21 302 used to measure the effect of severity of COPD and general health on work productivity and
22 303 regular activities²⁷ and HADS (14-items) will be used to measure the patient's emotional state
23 304 and the presence or absence of clinically significant anxiety and depression.²⁸ Sleep quality of
24 305 the participants will be measured using Pittsburgh Sleep Quality Index (PSQI)²⁹. Disease burden
25 306 will be measured as baseline data prior to the randomisation and post-intervention data.

307 Exercise capacity

308 Following a safety assessment for absolute and relative contraindications for field walking
309 tests³⁰, maximal exercise capacity will be assessed using the incremental shuttle walking test
310 (ISWT)³¹ and endurance shuttle walking test (ESWT).¹⁸ The ISWT and ESWT also include a
311 pre-test and post-test measure of SpO₂, blood pressure, Borg rating of breathlessness³², heart
312 rate, Borg rate of perceived exertion.³³ The sit-to stand test will be completed for five continuous
313 repetitions, to measure lower limb movement and strength.³⁴ All measures of exercise capacity
314 will be measured at baseline prior to the randomisation and post-intervention.

315 Physical activity

316 Subjective health-related physical activity will be measured with the International Physical
317 Activity Questionnaire (IPAQ)³⁵ at baseline prior to the randomisation and post-intervention.

318 Participants will be asked to wear an activity monitor (ActiGraph wGT3X-BT, ActiGraph,
 319 Pensacola, FL, USA), able to detect a range of PA intensities³⁶, on the right anterior hip during
 320 waking hours for seven days prior to attending PR (baseline) and for the seven consecutive days
 321 prior to their discharge assessment (follow-up); taking it off for water-based activities and sleep.
 322 The collection of physical activity data will coincide with a 7-day diet diary. Printed instructions
 323 will be provided to the participants regarding how to wear the monitor.

324 Full accelerometry methodology is provided in Table 3. Data will be processed as 60-s epoch
 325 files in ActiLife version 6.13.4 (ActiGraph, Pensacola, FL, USA). Non-wear will be defined as
 326 60-minutes of consecutive zero counts with allowance for 2-minutes of interruptions.³⁷
 327 Adherence to wearing the monitors will be assessed by examining the proportion of participants
 328 providing valid accelerometer data across a range of valid days ($\geq 1-7$ days) and minimum wear
 329 time ($\geq 1-12$ hours) thresholds. For reported group averages, only participants providing ≥ 4 valid
 330 days of ≥ 8 hours, for both time points will be included in the analyses.³⁸ Step count, time spent
 331 in different absolute intensity classifications of physical behaviours³⁹ and average movement
 332 intensity (activity counts per minute) will be reported. Time spent in physical activity matching
 333 participants' prescribed walking exercise intensity will be derived by aligning the average
 334 walking speed during the ESWT with the activity monitor counts per minute.

335

Table 3: Accelerometry data collection and processing parameters

Accelerometer Model	ActiGraph wGT3X-BT (version 6.13.4; firmware 1.9.2)
Serial number range	Twenty unique devices will be used ranging from MOS2E09190601 to MOS2E24190146 averaging six deployments per device (same serial used for baseline and follow-up wear periods)
Piezosensor orientation	Triaxial
Mode setup	Mode 29 (x, y, z, steps, lux)
Original sample rate	100 Hz (.gt3x file format)
Deployment method	Baseline: Fitted by research team on Day 0 (Baseline PR Assessment) Fitted by participant on Day 1 Follow-up: Fitted by research team Day 0 (11 th /12 th session) Fitted by participant on Day 1
Location worn	Anterior hip adjacent to the mid-line of the thigh
Requested days of wear	7 days of free-living (Day 1-7; 10,080 epochs)

Initialization	Not deployed in delay mode in order to standardised capture of Day 0 (00:00) with stop time based on date of first PR class (baseline) and data of discharge assessment (follow-up)
Wear instructions	Wear continuously except for sleep and water based activities
Non-wear appropriation	≥ 60 min of consecutive 0s with allowance for 2 minutes of interruptions were deemed biologically implausible and coded as non-wear
Valid day criteria	≥ 8 hours of valid waking wear time
Valid file	≥ 4 valid days for each of the two time points
Missing data	Data modelling or imputation will not be performed
Epoch length	60 seconds
Intensity classification (absolute)	Uniaxial (x-axis) cut-points as follows: Sedentary time <100 cpm; Light intensity 100-2019 cpm; Moderate intensity 2020-5998cpm; Vigorous intensity ≥ 5999 cpm (Moderate-to-vigorous intensity ≥ 2020 cpm)
Intensity classification (relative)	Uniaxial (x-axis) cut-points based on Endurance Shuttle Walk Test performance

336

337 Patient and Public Involvement

338 Adults living with COPD often tell us how having COPD impacts their lives and that they often
 339 find it challenging to know what they can do to better manage their condition. When they talk
 340 about their self-management strategies, it is clear that education and exercise support would be
 341 of value. Also, they revealed the necessity of a programme to support their condition and
 342 willingness to attend such a programme. Patients are generally positive about being able to
 343 access support but there is little available to them. The study was planned to fulfill the need of
 344 adults living with COPD. The delivery and adaptations of the trial intervention (Sri-Lankan
 345 specific PR) will also be informed by the adults living with COPD, their care-givers /family
 346 members and health care professionals. Priorities, experience, and preferences of the
 347 stakeholders will be utilized to design the PR. Health care professionals involved in the treatment
 348 of COPD at Central Chest Clinic will be involved in the recruitment as key informants and
 349 conduct of the study. The feasibility and acceptability of the PR intervention among adults living
 350 with COPD and healthcare staff involved in its delivery will be assessed in qualitative interviews
 351 at the end of the trial. The results of the trial will be disseminated through patient and public
 352 involvement events, local and international conference proceedings. As well as all the research

353 participants, stakeholders and individuals with COPD will be openly invited to take part in an
 354 event organized at the central chest clinic to reveal the study findings.

355

356 **Costing**

357 As part of this trial, the cost of creating a Sri-Lankan adapted PR programme will be calculated.
 358 This will include both single and recurrent costs. Single payments include the necessary costs to
 359 set up and run a programme, whilst recurrent cost refers to any item with a life expectancy of 1
 360 year or less and typically includes disposable materials.⁴⁰ The fixed costs will be captured prior
 361 to the first participant enrolling into the programme and the recurrent costs will be collected at
 362 the mid-stage of recruitment. An average cost per participant will be calculated. Table 4
 363 demonstrates the variables that will be used to calculate fixed and recurrent costs.

364

Table 4: The variables used to calculate fixed and recurrent costs (not an exhaustive list)

Fixed costs	Recurrent costs
Venue hire	Venue hire
Electrical equipment (laptop, printer, projector)	Staff time to conduct PR (assessment at baseline and discharge, conduct PR classes, telephone calls and data entry)
Equipment for PR (weights, treadmill, cycle ergometer, country-specific equipment, step-up box, chairs)	Disposable equipment (for blood glucose monitor, spirometer mouthpieces, nose-clips, glyceryl trinitrate spray)
Equipment for shuttle walking tests (cones, licences, stop watches, tape measure, electrical equipment to play audio)	Servicing costs (spirometer, PR equipment, specifically treadmills and cycle ergometers)
Equipment for PR assessment (height stadiometer, weight scales, sphygmomanometer, pulse oximeter, spirometer, calibration syringe, country-specific equipment)	Miscellaneous (Oxygen cylinders, questionnaire licences, stationery (paper))
Additional safety equipment (blood glucose monitor, Oxygen cylinder holder)	

Miscellaneous (filing cabinets, storage units, questionnaire translations, questionnaire licences, staff uniform)	
---	--

365

366

367 **Data management**

368 Data collected during the study will be entered into a database using Research Electronic Data
369 Capture (REDCap), which is a web-based platform.⁴¹ Access to the database will be via a secure
370 password protected web-interface. The participants will be identified by a study-specific
371 identification code. Data will be validated using real-time data entry validation and electronic
372 checks lead by the Independent Data Monitoring Committee (IDMC), established at the
373 University of Leicester, UK.

374 **Quantitative data analysis**

375 The data will be analyzed using IBM SPSS Statistics for Windows, Version 23.0. Data for
376 baseline and follow-up time-points will be presented as descriptive statistics as appropriate. No
377 inferential statistics will be performed due to the feasibility design of the trial.

378 **Qualitative data analysis**

379 Qualitative data will be analyzed using Thematic Analysis. This approach follows six distinct
380 stages: familiarization with data; generating initial codes; searching for themes; reviewing
381 themes; defining and naming themes and producing the report.⁴² The responsible investigator
382 will carry out initial coding and a sample of focus group transcripts will be coded by a second
383 member of the team to improve consistency and to enhance interpretive authenticity. Throughout
384 the data analysis, the team will meet to discuss and review emerging themes and search the
385 accounts that provide contesting views of the same phenomena. Close attention will be paid to
386 the complexity and interactions inherent in the focus group data.⁴³

387 **Adverse events**

1
2
3 388 All adverse events and serious adverse events will be recorded on an adverse event log, within
4 389 study trial management paperwork, case report forms and REDCap. There will be no formal
5
6 390 interim analysis of data due to the feasibility nature of the trial. The IDMC will review high level
7
8 391 safety data. Adverse events will be monitored at least every month, and as needed on an ad hoc
9
10 392 basis, to ensure the continuing safety of the participants. The Scientific Committee will
11
12 393 determine the need to terminate the trial. Participants who experience any such event will be
13
14 394 directed to the appropriate hospital and all the necessary care will be ensured and followed-up
15
16 395 until the participant has resolved or stabilized.
17

18 396

21 397 **Ethics and dissemination**

22
23 398 Ethical approval was obtained from the ethics review committee of the Faculty of Medical
24
25 399 Sciences, University of Sri Jayewardenepura (FMS/USJP ERC 64/19) and the University of
26
27 400 Leicester, United Kingdom (26770). Further permission for the proposed study will be obtained
28
29 401 from the relevant authority at the Central Chest Clinic, Colombo, Sri Lanka. Privacy and the
30
31 402 confidentiality of all information and identities of participants will be strictly maintained and will
32
33 403 not be disclosed when publishing the results of the study. A copy of the test results obtained will
34
35 404 be provided to each participant at the end of the trial for subsequent follow-up and treatment at
36
37 405 the clinic. Compensation for travelling will be provided to all the participants. All study
38
39 406 documents will be translated to Sinhala and Tamil to ensure clear communication. Participation
40
41 407 will be without compulsion and each participant has the right to withdraw at any time, without
42
43 408 providing a reason. Consent form and data sheets will be securely stored in a separate locked
44
45 409 cupboard. Study computers will be password protected. The participants (adults living with
46
47 410 COPD) of the phase 1 study also will be provided the opportunity to participate the PR. All the
48
49 411 data will be stored safely up to 6 years and after 6 years consent form and data sheets will be
50
51 412 disposed of appropriately. Study team and IDMC only will have access to final trial dataset. Data
52
53 413 from the Global RECHARGE Core Dataset will be made available following the completion of
54
55 414 this project and we are considering the best tools to use to make this database available to the
56
57 415 wider community. Any modifications of the protocol will be updated on trial registry (ISRCTN)
58
59 416 and will be informed to the ethics review committee and the participants. Participants will be

1
2
3 417 provided the provisions for re-consenting after any change of the approved protocol. It will be
4
5 418 made clear in the publication of trial findings.
6
7

8 419

9
10 420

11
12
13 421 **Author affiliations**

14
15 422 ¹Faculty of Health Sciences, KAATSU International University, Sri Lanka

16 423 ²Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-
17
18 424 Respiratory, University Hospitals of Leicester NHS Trust, UK

19 425 ³Department of Respiratory Sciences, University of Leicester, Leicester, UK,

20 426 ⁴Sports Medicine Unit, Colombo South Teaching Hospital, Kalubowila, Sri Lanka

21 427 ⁵Department of Nursing and Midwifery, Faculty of Allied Health Sciences, University of Sri
22
23 428 Jayewardenepura, Sri Lanka

24 429 ⁶National Hospital of Sri Lanka and Central Chest Clinic, Colombo, Sri Lanka

25 430 ⁷Primary Care Respiratory Group, Sri Lanka

26 431 ⁸Faculty of Health, University of Plymouth, UK

27 432 ⁹School of Sport, Exercise and Health Sciences, Loughborough University, UK

28 433 ¹⁰Department of Economics, University of Sheffield, Sheffield, UK

29 434 ¹¹Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka
30
31
32
33
34
35
36
37
38
39 435

40
41
42 436 **Author contribution**

43
44 437 All authors (Akila R Jayamaha, Chamilya H Perera, Mark W Orme, Amy V Jones, Upendra K D
45 438 C Wijayasiri, Thamara D Amarasekara, Ravini de S Karunatillake, Amitha C Fernando,
46 439 Seneviratne A L P De S., Andy Barton, Rupert Jones, Zainab K Yusuf, Ruhme B Miah, Dominic
47 440 Malcolm, Jesse A Matheson, Robert C Free, Adrian Manise, Michael C Steiner, Savithri W
48 441 Wimalasekera, Sally J Singh) have substantially contributed to the conception and design of the
49 442 study. Akila R Jayamaha drafted the manuscript. All authors of the paper have revised the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 443 content and approved the final version to be published. All authors are accountable for all aspects
4
5 444 of the work.

6
7
8 445 **Funding** This research was funded by the National Institute for Health Research (NIHR)
9
10 446 (17/63/20) using UK aid from the UK Government to support global health research. The views
11
12 447 expressed in this publication are those of the author(s) and not necessarily those of the NIHR or
13
14 448 the UK Department of Health and Social Care.

15
16 449 **Competing interests** None declared.

17
18 450

19
20 451 [insert figure caption]

21
22
23 452 Figure 1: Flow of participant of the three phases of the study

24
25
26 453


27
28 454 References

- 29
30
31 455 1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for
32
33 456 the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the
34
35 457 GOLD science committee report 2019. *Eur Respir J.* 2019;53(5).
- 36 458 2. Alwan A. Global Status Report on Non-Communicable Diseases. WHO, 2010
- 37
38 459 3. World Health Organization. Global surveillance, prevention and control of Chronic
39
40 460 Respiratory Diseases, Switzerland, 2007; 22-23.
- 41 461 4. Amarasiri L, Fernando A, Gunasekara K, Gunasinghe W, Madegedara D, Wickramasinghe
42
43 462 R. The prevalence of Chronic Obstructive Pulmonary Disease in Sri Lanka. *European*
44
45 463 *Respiratory Journal*, 2017; 2017(50):1212.
- 46 464 5. World Health Organization. WHO strategy for prevention and control of chronic respiratory
47
48 465 diseases, Geneva, 2017.
- 49
50 466 6. Yasaratne D, Dharmage SC. Letter from Sri Lanka. *Respirology.* 2020;25:339-41.
- 51
52 467 7. Pinnock H, Kendall M, Murray SA, Worth A, Levack P, Porter M, et al. Living and dying
53
54 468 with severe chronic obstructive pulmonary disease: Multi-perspective longitudinal qualitative
55
56 469 study. *BMJ.* 2011;342:268.

- 1
2
3 470 8. Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K. Comment Exercise and pulmonary
4 471 rehabilitation for people with chronic lung disease in LMICs : challenges and opportunities.
5 472 *Lancet Respir* [Internet]. 2019;7(12):1002–4.
6
7 473 9. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American
8 474 Thoracic Society Documents American Thoracic Society / European Respiratory Society
9 475 Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med*. 2006;173(May):1390-
10 476 413.
11
12 477 10. Mccarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y, et al. Pulmonary
13 478 rehabilitation for chronic obstructive pulmonary disease (Review). *Cochrane Database Syst*
14 479 *Rev*. 2015;2015(2).
15
16 480 11. Jones AW, Taylor A, Gowler H, Kelly NO, Ghosh S, Bridle C. Systematic review of
17 481 interventions to improve patient uptake and completion of pulmonary rehabilitation in
18 482 COPD. *ERJ Open Res*. 2017;3.
19
20 483 12. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit
21 484 2013 statement: Defining standard protocol items for clinical trials. *Chinese J Evidence-Based*
22 485 *Med*. 2013;13(12):1501–7.
23
24 486 13. Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on
25 487 pulmonary rehabilitation in adults: accredited by NICE. *Thorax*. 2013;68:ii1-ii30.
26
27 488 14. Ries AL, Bauldoff GS, Casaburi R, Mahler DA, Rochester CL, Herrerias C. Pulmonary
28 489 Rehabilitation; Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest*.
29 490 2007;131(5):4S-42S.
30
31 491 15. Blackstock FC, Evans RA. Rehabilitation in lung diseases: ‘Education’ component of
32 492 pulmonary rehabilitation. *Respirology*. 2019;24(9):863–70
33
34 493 16. Spencer LM, McKeough ZJ. Maintaining the benefits following pulmonary rehabilitation:
35 494 Achievable or not? *Respirology*. 2019;24(9):909–15.
36
37 495 17. Armstrong M, Vogiatzis I. Personalized exercise training in chronic lung diseases.
38 496 *Respirology*. 2019;24(9):854–62.
39
40 497 18. Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk :
41 498 a new field test for the assessment of endurance capacity in chronic obstructive pulmonary
42 499 disease. *Thorax*. 1999;54(2):213–22
43
44 500 19. Yasuda H, Yamaya M, Nakayama K, Ebihara S, Sasaki T, Okinaga S, et al. Increased
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 501 Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease. *Am*
4 502 *J Respir Crit Care Med.* 2005;171:1246–51.
- 5
6 503 20. Durmin JVGA, Womersley J. Body fat assessed from total body density and its estimation
7 504 from skinfold thickness: measurements on 481 men and women aged from 16 to 72 Years. *Br*
8 505 *J Nutr.* 1974;32:77–96.
- 9
10 506 21. Doña E, Olveira C, Palenque FJ, Porrás N, Dorado A, Martín-valero R, et al. Body
11 507 Composition Measurement in Bronchiectasis: Comparison between Bioelectrical Impedance
12 508 Analysis, Skinfold Thickness Measurement, and Dual-Energy X-ray Absorptiometry before
13 509 and after Pulmonary Rehabilitation. *J Acad Nutr Diet.* 2018;118(8):1464–73.
- 14
15 510 22. Lanerolle MD, Lanerolle P, Atukorala S, Silva A De. Enhancing the accuracy of bio
16 511 impedance analysis in assessing total body water. *Int J Body Compos Res.* 2012;10(1):29–34.
- 17
18 512 23. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the
19 513 Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with
20 514 chronic obstructive pulmonary disease. *Thorax.* 1999;54:581–6.
- 21
22 515 24. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
23 516 preliminary testing of the new five-level version of EQ-5D (EQ-5D5L). *Quality of Life*
24 517 *Research.* 2011;20(10):1727-736.
- 25
26 518 25. Van der Molen T, Willemse BW, Schokker S, et al. Development, validity and
27 519 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes.* 2003;1:13.
- 28
29 520 26. Papaioannou M, Pitsiou G, Manika K, Kontou P, Zarogoulidis P, Sichletidis L, Kioumis IP.
30 521 COPD assessment test: A simple tool to evaluate disease severity and response to treatment.
31 522 *J of Chronic Obstructive Pulmonary Disease.* 2014;11:489- 95.
- 32
33 523 27. Reilly MC, Zbrozek IAS, Dukes EM. The Validity and Reproducibility of a Work
34 524 Productivity and Activity Impairment Instrument. *Pharmacoeconomics.* 1993;4(5):353–65.
- 35
36 525 28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica*
37 526 *Scandinavica.* 1983;67(6):361-70.
- 38
39 527 29. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new
40 528 instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28:193–213
- 41
42 529 30. Weisman IM, Marciniuk D, Martinez FJ, Sciruba F, Sue D, Myers J, et al. American
43 530 Thoracic Society / American College of Chest Physicians ATS / ACCP Statement on
44 531 Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003;167:211–77.

- 1
2
3 532 31. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking
4 533 test of disability in patients with chronic airways obstruction. *Thorax*. 1992;47(12):1019-24.
5
6 534 32. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with
7 535 respiratory disease. *Med Sci Sports Exerc*. 1994;26:1078-1081.
8
9 536 33. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14:377-
10 537 381
11
12 538 34. Jones SE, Kon SSC, Canavan JL, Patel MS, Clark AL, Nolan CM, et al. The five-repetition
13 539 sit-to-stand test as a functional outcome measure in COPD. *Thorax*. 2013;68:1015-20.
14
15 540 35. Booth M: Assessment of physical activity: An International perspective. *Research Quarterly*
16 541 *for Exercise and Sport*. 2000, 71 (2): 114-120.
17
18 542 36. Bassett DR, John D. Use of pedometers and accelerometers in clinical populations: validity
19 543 and reliability issues. *Phys Ther Rev*. 2010;15:135-42.
20
21 544 37. Choi L, Liu Z, Matthews CE, Buchowski MS. Validation of accelerometer wear and nonwear
22 545 time classification algorithm. *Med Sci Sports Exerc*. 2011;43:357-64.
23
24 546 38. Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, et al.
25 547 Standardizing the analysis of physical activity in patients with COPD following a pulmonary
26 548 rehabilitation program. *Chest* 2014 Aug;146(2):318-327
27
28 549 39. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in
29 550 the United States measured by accelerometer. *Med Sci Sports Exerc* 2008 Jan;40(1):181-188.
30
31 551 40. Lucas AO, Gilles HM. Approaches to economic evaluation. *Short Textbook of Public Health*
32 552 *Medicine for the Tropics*. 2002. CRC Press.
33
34 553 41. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap
35 554 consortium: Building an international community of software platform partners. *J Biomed*
36 555 *Inform*. 2019;95.
37
38 556 42. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3:77-101
39
40 557 43. Maguire M, Delahunt B. Doing a Thematic Analysis : A Practical, Step-by-Step Guide for
41 558 Learning and Teaching Scholars. *AISHE-J*. 2017;8(3):3351-14.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Appendices

Information sheet

Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

I am Prof. S. W. Wimalasekera, of Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura. I and my team of health care personnel are, conducting a research on “Testing the Feasibility and Acceptability of a Culturally Appropriate Hospital-Based Pulmonary Rehabilitation (PR) Programme for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka”. I invite you to participate in the study. Please take time and read the following information carefully before giving your consent. You are free to ask questions to clarify facts which are not clear or ask for more information if you need.

Purpose of the study

The purpose of this study is to devise an appropriate PR programme and then determine the feasibility and acceptability of this programme for adults living with COPD in Sri Lanka and assess the potential for a future trial of its effectiveness.

When you participate you will be required to do the following

You will be requested to participate several components of the study.

You will participate in a group discussion conducted in a quiet room in the clinic (conference hall) with very minimal disturbances. At the beginning of the discussion you will answer some questions regards your personal information, (age, gender, history of the disease condition). Then the interviewer will ask some questions regarding your thoughts and ideas about pulmonary rehabilitation. You and your group members can freely comment on the questions or can add your ideas to the discussion. The interview takes around forty-five minutes of time.

You will also participate in a feasibility trial which you will be allocated to one of the two groups. One group will receive usual care and PR and the other group will receive only usual care which consists of pharmacological treatment and brief information about disease condition, medication and inhaler techniques. PR is typically a 6-week rolling programme and consisting of 12 sessions in total, delivered twice a week. Sessions usually last approximately two hours, with one hour for exercise training and one hour for education. Some routine and specific test and measurements will be taken before and after the intervention will describe any changes in the health of the adults living with COPD.

If you are allocated to the group who receive the PR, you will be asked to share your experiences regarding the PR and subjected modification and opinions on pulmonary rehabilitation.

In order to maintain accuracy, and to keep records, your discussion will be recorded by the research team members with your permission. Your participation in the project will remain confidential and the provision of your name and address is necessary for us to maintain records. Any personal information gathered during the study will not be disclosed to a third party. Your responses to the questions and will

1
2
3 only be used for the purpose of this project. You can be assured that you will remain anonymous if you
4 take part in the project. Your participation in this project is entirely voluntary. You are not obliged to take
5 part. If you do not wish to take part, you can withdraw without giving a reason and your medical care will
6 not be affected, further you will not be contacted again. Similarly, if you do agree to participate, you are
7 free to withdraw at any time during the project.
8
9
10

11 **What are the possible benefits of taking part?**

12
13 By participating in the study, you will contribute to develop a PR programme which helps to improve the
14 quality of life of the adults living with COPD. As well as you will contribute to determine the feasibility
15 and acceptability of this programme within the health care system in Sri Lanka.
16
17
18

19 **What are the possible disadvantages and risks of taking part?**

20
21 You will be undertaking some physical tests as part of the research. Therefore, there may be a very small
22 risk of falls, breathlessness, changes in blood pressure and changes in heart rate. However, these risks are
23 very rare, and trained staff and emergency equipment will be available to deal with any serious events.
24 Participants who experience any such event will be directed to the appropriate hospital and all the
25 necessary care will be ensured and followed-up until the participant has resolved or stabilized.
26
27
28

29 **What will happen if you don't carry on with the study?**

30
31 If you withdraw from the study all the information and data collected from you, to date, will be destroyed
32 and your name would be removed from all the research study files. There will not be any loss or impact
33 on your routine medical care which you are entitled to.
34
35
36

37 **What will happen to the results of the research study?**

38
39 The results of all the participants of the study will be used for scientific research. All data will be
40 available only to the researchers and information provided will be strictly confidential. Your participation
41 in the study is highly appreciated. Privacy and confidentiality of data gathered is completely secure and
42 will be used only for research purposes. If you have any questions or any concerns with regards to the
43 study and need further information you can call the telephone number listed below. Further you can send
44 any complaint to the above postal address or email address.
45
46
47

48 Yours faithfully

49 Prof. S.W. Wimalasekera

50 Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura

51 T.P No. 0777487203 e-mail : savithriww@yahoo.com

52 Ethics Review Committee – University of Sri Jayewardenepura - +94 11 2758000 Ext 4075e
53
54
55
56
57
58
59
60

Consent Form: Randomised Controlled Feasibility Trial

Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka

- 1. Have you read the information sheet? (please keep a copy for yourself) YES/NO
- 2. Have you had an opportunity to discuss this and ask any questions? YES/NO
- 3. Have you had satisfactory answers to all your questions? YES/NO
- 4. Have you received enough information about the study? YES/NO
- 5. Who explained the study to you-----
- 6. Do you understand that you are free to withdraw from the study at any time,
without having to give a reason YES/NO
- 7. All personal details will be treated as STRICTLY CONFIDENTIAL.
Do you give your permission for these individuals to have access to the records? YES/NO
- 8. Have you had sufficient time to come to your decision? YES/NO
- 9. Do you agree to take part in this study? YES/NO

Participant's signature ----- Date-----

By the Witness

I have been present while the procedure was explained to the participant and I have witness his/ her willingness to take part in the study.

Signature of witness----- Date-----

(The witness should be a person not connected to the study)

Name -----

Contact details-----